# NEWSROOM - PharmaShots


## Posts

- [Accumulus Technologies Launches the Accumulus Connector, Delivering Live Integration Across Regulatory Systems](https://newswire.pharmashots.com/accumulus-technologies-launches-the-accumulus-connector-delivering-live-integration-across-regulatory-systems/): SAN FRANCISCO, March 24, 2026 (GLOBE NEWSWIRE) -- Accumulus Technologies today announced the launch of the Accumulus Connector (“Connector”), a new platform capability that extends the Accumulus platform into customers’ existing technology stacks, transforming them into a direct, real-time channel for global regulatory collaboration.
- [Dr. James Burt Joins ProductLife Group as CEO](https://newswire.pharmashots.com/dr-james-burt-joins-productlife-group-as-ceo/): PARIS, March 23, 2026 (GLOBE NEWSWIRE) -- ProductLife Group (PLG), a global provider of consulting and outsourcing services for the life sciences industry, has appointed Dr.
- [EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH](https://newswire.pharmashots.com/eau-guidelines-upgrade-aquablation-therapy-to-strong-surgical-recommendation-for-bph/): SAN JOSE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the European Association of Urology (EAU) Guidelines for male lower urinary tract symptoms (LUTS), which include an upgrade of Aquablation therapy to a strong recommendation as a surgical treatment option for men with benign prostatic hyperplasia (BPH).
- [Philips convenes the Annual General Meeting of Shareholders 2026](https://newswire.pharmashots.com/philips-convenes-the-annual-general-meeting-of-shareholders-2026/): Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes.
- [Philips proposes new appointment and re-appointments to its Supervisory Board and CEO re-appointment](https://newswire.pharmashots.com/philips-proposes-new-appointment-and-re-appointments-to-its-supervisory-board-and-ceo-re-appointment/): John DeFord proposed as new member of the Supervisory Board.
- [Teva Releases Q1 2026 Aide Memoire](https://newswire.pharmashots.com/teva-releases-q1-2026-aide-memoire/): TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026](https://newswire.pharmashots.com/teva-to-host-conference-call-to-discuss-first-quarter-2026-financial-results-at-8-a-m-et-on-april-29-2026/): TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [Curia Expands Glasgow Manufacturing Capacity and Enhances Cell Line Development Platform](https://newswire.pharmashots.com/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform/): March 19, 2026 09:00 ET | Source: Curia Global, Inc.
- [Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia](https://newswire.pharmashots.com/tilray-medical-announces-major-expansion-of-medical-cannabis-portfolio-in-australia/): March 19, 2026 07:00 ET | Source: Tilray Brands, Inc.
- [SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment](https://newswire.pharmashots.com/sk-pharmteco-reaffirms-three-business-unit-strategy-strengthens-global-gene-therapy-business-unit-with-funding-commitment/): March 19, 2026 04:00 ET | Source: SK pharmteco Inc.
- [AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors](https://newswire.pharmashots.com/aim-immunotech-announces-final-approval-of-novel-cancer-therapy-patent-in-japan-combining-ampligen-with-checkpoint-inhibitors/): March 18, 2026 08:36 ET | Source: AIM ImmunoTech Inc.
- [Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting](https://newswire.pharmashots.com/zymeworks-announces-presentations-for-ziihera-zanidatamab-hrii-at-2026-aacr-annual-meeting/): March 18, 2026 07:46 ET | Source: Zymeworks Inc.
- [Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice](https://newswire.pharmashots.com/global-survey-reveals-pet-owners-lack-awareness-of-parasite-risks-and-seek-clearer-prevention-advice/): 43% of pet owners report that their pets experienced parasite infections, with 75% looking for clearer parasite prevention advice.
- [Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting](https://newswire.pharmashots.com/zymeworks-to-present-clinical-and-preclinical-data-on-adc-programs-including-novel-ras-adc-platform-at-aacr-annual-meeting/): March 17, 2026 17:02 ET | Source: Zymeworks Inc.
- [Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA](https://newswire.pharmashots.com/adagenes-muzastotug-adg126-to-be-highlighted-in-two-presentations-at-the-2026-american-association-for-cancer-research-aacr-annual-meeting-in-san-diego-ca/): March 17, 2026 16:35 ET | Source: Adagene Inc.
- [Alamar Biosciences Launches NULISAseq™ Neuro 220 Panel, its largest precision proteomics panel with the sensitivity and specificity to advance neurological disease research](https://newswire.pharmashots.com/alamar-biosciences-launches-nulisaseq-neuro-220-panel-its-largest-precision-proteomics-panel-with-the-sensitivity-and-specificity-to-advance-neurological-disease-research/): New panel expands coverage for Alzheimer’s and Parkinson’s diseases including 15 new biomarkers developed with support from The Michael J.
- [SK pharmteco Announces Successful FDA Inspection of Small Molecule Manufacturing Facility in La Porte, Texas](https://newswire.pharmashots.com/sk-pharmteco-announces-successful-fda-inspection-of-small-molecule-manufacturing-facility-in-la-porte-texas/): March 17, 2026 09:03 ET | Source: SK pharmteco Inc.
- [Imprivata Introduces New Advanced Access Management and Passwordless Authentication Capabilities to Enhance Clinical Efficiency, Security, and Essential Eight Compliance](https://newswire.pharmashots.com/imprivata-introduces-new-advanced-access-management-and-passwordless-authentication-capabilities-to-enhance-clinical-efficiency-security-and-essential-eight-compliance/): MELBOURNE, March 16, 2026 (GLOBE NEWSWIRE) -- Imprivata, a leading provider of access management solutions for healthcare and other mission-critical industries, today introduced comprehensive new capabilities designed to help Australian healthcare organisations improve clinical workflow efficiency while strengthening cyber security and compliance with the Australian Cyber Security Centre’s (ACSC) Essential Eight mitigation strategies.
- [Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates](https://newswire.pharmashots.com/junshi-biosciences-announces-2025-full-year-financial-results-and-provides-corporate-updates/): SHANGHAI, March 13, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2025 and provided corporate updates.
- [PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy](https://newswire.pharmashots.com/procept-biorobotics-announces-international-launch-of-the-hydros-robotic-system-expanding-global-access-to-ai-enabled-aquablation-therapy/): SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH).
- [SK pharmteco Announces CGMP Qualification of its Commercial-Scale Viral Vector Manufacturing Facility in France](https://newswire.pharmashots.com/sk-pharmteco-announces-cgmp-qualification-of-its-commercial-scale-viral-vector-manufacturing-facility-in-france/): March 12, 2026 04:04 ET | Source: SK pharmteco Inc.
- [Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention](https://newswire.pharmashots.com/io-therapeutics-inc-announces-publication-of-studies-on-the-companys-rxr-agonist-compound-irx4204-for-breast-cancer-prevention/): March 11, 2026 11:10 ET | Source: Io Therapeutics, Inc.
- [Philips expands digital pathology portfolio with cloud-enabled Philips IntelliSite Pathology Solution on HealthSuite](https://newswire.pharmashots.com/philips-expands-digital-pathology-portfolio-with-cloud-enabled-philips-intellisite-pathology-solution-on-healthsuite/): Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the expansion of its digital pathology portfolio with new cloud-enabled capabilities designed to help healthcare organizations scale digital diagnostics, improve productivity, and advance their transformation to fully digital workflows.
- [TekniPlex Healthcare to Participate in CMEF 2026, Showcasing Next-Generation Medical Materials Science Solutions and Precision Tubing Technologies](https://newswire.pharmashots.com/tekniplex-healthcare-to-participate-in-cmef-2026-showcasing-next-generation-medical-materials-science-solutions-and-precision-tubing-technologies/): Wayne, PA, March 11, 2026 (GLOBE NEWSWIRE) -- TekniPlex Healthcare, a global leader in advanced materials science and precision manufacturing for the medical and healthcare industries, announced its participation at the China International Medical Equipment Fair (CMEF) 2026.
- [Philips connects patient monitoring and diagnostics to advance platform-based care intelligence at HIMSS26](https://newswire.pharmashots.com/philips-connects-patient-monitoring-and-diagnostics-to-advance-platform-based-care-intelligence-at-himss26/): Amsterdam, the Netherlands, and Las Vegas, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today highlighted how open, interoperable, AI-enabled platforms can help health systems connect continuous patient monitoring with diagnostic insights – bringing the patient story together across time and across specialties.
- [Egg Medical Presents CRT 2026 Data Demonstrating a Responsible Path to Light Lead and Lead-Apron Free Protection](https://newswire.pharmashots.com/egg-medical-presents-crt-2026-data-demonstrating-a-responsible-path-to-light-lead-and-lead-apron-free-protection/): March 10, 2026 09:00 ET | Source: Egg Medical, Inc.
- [Menarini nears €4.9 billion in 2025 and focuses on talent and AI as ‘giant’ players enter pharma](https://newswire.pharmashots.com/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma/): FLORENCE, Italy, March 09, 2026 (GLOBE NEWSWIRE) -- 2025 was a “positive year” for Menarini, which is celebrating its 140th anniversary this year, despite considerable global “turbulence”.
- [Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications](https://newswire.pharmashots.com/junshi-biosciences-announces-nmpa-acceptance-of-new-drug-applications-for-toripalimab-injection-subcutaneous-across-12-indications/): SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the new drug applications (the “NDAs”) for the company’s product, toripalimab injection (subcutaneous injection [code: JS001sc]), for 12 indications in the treatment of tumors has been accepted by the National Medical Products Administration (“NMPA”).
- [Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China](https://newswire.pharmashots.com/rapport-therapeutics-and-tenacia-biotechnology-announce-strategic-collaboration-for-the-development-and-commercialization-of-rap-219-in-greater-china/): March 09, 2026 07:00 ET | Source: Rapport Therapeutics, Inc.
- [CAPHRA Says Nicotine Should Not Be Criminalised Over Illicit Vape Products](https://newswire.pharmashots.com/caphra-says-nicotine-should-not-be-criminalised-over-illicit-vape-products/): WELLINGTON, New Zealand, March 09, 2026 (GLOBE NEWSWIRE) -- The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) says the rise of etomidate-laced “zombie vapes” in parts of Asia is a serious criminal and public health problem, but warns governments not to use it as an excuse to crack down on safer nicotine products used by adults to quit smoking.
- [Claritas iPET™ Approved by Australia TGA to Supply the Medical Software Device for Image Processing Enabling Diagnostic Quality Images from Short Scan Time and/or Low Dose PET, PET-CT/MRI Scans](https://newswire.pharmashots.com/claritas-ipet-approved-by-australia-tga-to-supply-the-medical-software-device-for-image-processing-enabling-diagnostic-quality-images-from-short-scan-time-and-or-low-dose-pet-pet-ct-mri-scan/): LONDON and SYDNEY, March 06, 2026 (GLOBE NEWSWIRE) -- Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specializing in state-of-the-art image enhancement, noise reduction, segmentation and quantification, and related AI technologies, is pleased to announce that the Australian regulatory agency for medicines and medical devices, namely, the Therapeutic Goods Administration (TGA) has approved the software device, Claritas iPET™ for supply in Australia.
- [Esaote launches the new MyLabTM E85 GTS ultrasound system in Vienna](https://newswire.pharmashots.com/esaote-launches-the-new-mylabtm-e85-gts-ultrasound-system-in-vienna/): VIENNA, Austria, March 05, 2026 (GLOBE NEWSWIRE) -- Easy to transport, featuring compact size and high-quality images, developed to revolutionise and facilitate the work of interventional radiologists all around the world.
- [Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder](https://newswire.pharmashots.com/helus-pharma-announces-topline-results-in-phase-2-signal-detection-study-for-hlp004-in-patients-with-generalized-anxiety-disorder/): This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.
- [Philips unveils Rembra CT at ECR 2026, setting a new benchmark for speed and patient access designed to support diagnostic confidence for acute and high-demand imaging environments](https://newswire.pharmashots.com/philips-unveils-rembra-ct-at-ecr-2026-setting-a-new-benchmark-for-speed-and-patient-access-designed-to-support-diagnostic-confidence-for-acute-and-high-demand-imaging-environments/): Amsterdam, the Netherlands and Vienna, Austria – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced Rembra [3], its next-generation radiology CT system designed for the realities of acute and high-demand imaging.
- [On World Hearing Day, Hearing Research International Launches to Accelerate the Future of Hearing Health and Deaf Studies](https://newswire.pharmashots.com/on-world-hearing-day-hearing-research-international-launches-to-accelerate-the-future-of-hearing-health-and-deaf-studies/): (Toronto, Canada) - On World Hearing Day, Hearing Research International officially launches as an international research foundation dedicated to advancing innovative, life-changing research in Hearing Health and Deaf Studies, positioning this work on the world stage and investing in the future of Hearing Health and Deaf Studies to improve lives.
- [Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug](https://newswire.pharmashots.com/teva-and-blackstone-life-sciences-announce-400-million-strategic-growth-capital-agreement-to-advance-duvakitug/): PARSIPPANY, N.J. and CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- [Resmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach](https://newswire.pharmashots.com/resmeds-global-sleep-survey-reveals-sleep-is-one-of-the-top-health-priorities-but-quality-rest-remains-out-of-reach/): March 03, 2026 03:00 ET | Source: Resmed, Inc.
- [Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials](https://newswire.pharmashots.com/kyowa-kirin-announces-discontinuation-of-rocatinlimab-clinical-trials/): TOKYO AND PRINCETON, Japan and the U.S., March 03, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd.
- [Cirrus Therapeutics Announces Strategic Expansion to Singapore and Other Key Updates Supporting its Growth as a Leading Global Ocular Immunology Company](https://newswire.pharmashots.com/cirrus-therapeutics-announces-strategic-expansion-to-singapore-and-other-key-updates-supporting-its-growth-as-a-leading-global-ocular-immunology-company/): March 03, 2026 08:00 ET | Source: Cirrus Therapeutics, Inc.
- [Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026](https://newswire.pharmashots.com/smithnephew-to-feature-leading-rotator-cuff-repair-portfolio-including-new-tendon-seam-repair-system-and-regeneten%e2%97%8a-bioinductive-implant-at-aaos-2026/): Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase its unrivalled portfolio for rotator cuff repair (RCR) during the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans this week.
- [Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing](https://newswire.pharmashots.com/zymeworks-and-royalty-pharma-enter-into-250-million-royalty-backed-note-financing/): VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc.
- [Biomimetic Innovations Ltd Announces Upcoming Clinical Study of OsStic™ Injectable Synthetic Bone Void Filler in Tibial Plateau Fracture Fixation](https://newswire.pharmashots.com/biomimetic-innovations-ltd-announces-upcoming-clinical-study-of-osstic-injectable-synthetic-bone-void-filler-in-tibial-plateau-fracture-fixation/): SHANNON, Ireland, March 02, 2026 (GLOBE NEWSWIRE) -- Biomimetic Innovations Ltd, an affiliate of PBC Biomed, an Irish medical device company specialising in biomimetic materials, today announced approval by MHRA for a first-in-human clinical study evaluating the safety and early performance of OsStic™ in periarticular fractures.
- [Pineal Capital Management Issues Open Letter to the Board of Teladoc Health, Inc.](https://newswire.pharmashots.com/pineal-capital-management-issues-open-letter-to-the-board-of-teladoc-health-inc/): Teladoc Health, Inc.
- [FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option](https://newswire.pharmashots.com/fda-approves-hernexeos-the-first-targeted-therapy-for-adults-with-her2-mutant-advanced-nsclc-as-an-initial-treatment-option/): Ingelheim, Germany and Ridgefield, Conn. [DATE] -- The U.S.
- [Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026](https://newswire.pharmashots.com/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026/): BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Curium, a world leading nuclear medicine company dedicated to using cutting-edge technology and innovative science to personalize diagnoses and treatments for patients with cancer, today announced the first dosimetry and pharmacokinetics (PK) data from a substudy of the ongoing pivotal Phase 3 ECLIPSE clinical trial (NCT05204927).
- [Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics](https://newswire.pharmashots.com/boehringer-ingelheim-licenses-novel-oral-therapeutics-program-for-immune-diseases-from-sitryx-therapeutics/): Ingelheim, Germany, Oxford, UK and Boston, USA, 26, February 2026 – Boehringer Ingelheim and Sitryx Therapeutics (“Sitryx”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory diseases, today announced that Boehringer has acquired an exclusive license for a preclinical, small molecule program from Sitryx.
- [Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)](https://newswire.pharmashots.com/junshi-biosciences-announces-strategic-collaboration-with-antengene-to-evaluate-combination-therapy-with-js207-pd-1-vegf-bsab-and-atg-037-oral-cd73-inhibitor/): SHANGHAI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the company has entered into the strategic collaboration with Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK).
- [Teva to Present at the Upcoming Investor Conferences in March](https://newswire.pharmashots.com/teva-to-present-at-the-upcoming-investor-conferences-in-march/): PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [Countdown For A Cure Raises Over $1 Million at 2026 Evening of Energy Gala](https://newswire.pharmashots.com/countdown-for-a-cure-raises-over-1-million-at-2026-evening-of-energy-gala/): A Media Snippet accompanying this announcement is available by clicking on this link.
- [Gyder Surgical announces first commercial surgical cases in the United States performed by Dr. Paul M. Lombardi, M.D., at the Tri-County Orthopedics’ Joint Replacement Institute outpatient center](https://newswire.pharmashots.com/gyder-surgical-announces-first-commercial-surgical-cases-in-the-united-states-performed-by-dr-paul-m-lombardi-m-d-at-the-tri-county-orthopedics-joint-replacement-institute-outpatient-cen/): PALO ALTO, Calif. and MULGRAVE, Australia, Feb.
- [U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults](https://newswire.pharmashots.com/u-s-food-and-drug-administration-fda-accepts-tevas-new-drug-application-nda-for-olanzapine-extended-release-injectable-suspension-tev-749-for-the-once-monthly-treatment-of-schizophre/): PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- [Philips publishes its Annual Report 2025](https://newswire.pharmashots.com/philips-publishes-its-annual-report-2025/): Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025.
- [Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services](https://newswire.pharmashots.com/fortrea-expands-executive-team-appointing-oren-cohen-as-chief-medical-officer-and-scott-dove-as-president-of-clinical-pharmacology-services/): DURHAM, N.C., Feb.
- [Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease](https://newswire.pharmashots.com/teva-and-sanofis-duvakitug-phase-2b-maintenance-data-demonstrated-clinically-meaningful-durable-efficacy-in-ulcerative-colitis-and-crohns-disease/): Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data.
- [Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway](https://newswire.pharmashots.com/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway/): SAN DIEGO, CA, Feb.
- [Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution](https://newswire.pharmashots.com/helus-pharma-appoints-michael-cola-as-chief-executive-officer-to-lead-next-phase-of-scale-and-execution-2/): This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.
- [Philips proposes to re-appoint CEO Roy Jakobs](https://newswire.pharmashots.com/philips-proposes-to-re-appoint-ceo-roy-jakobs/): Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Roy Jakobs is proposed to be re-appointed as its President/Chief Executive Officer and member of the Board of Management.
- [Philips delivers full year 2025 with growth acceleration, strong margin expansion and solid cash flow; announces 2026-2028 targets at Capital Markets Day](https://newswire.pharmashots.com/philips-delivers-full-year-2025-with-growth-acceleration-strong-margin-expansion-and-solid-cash-flow-announces-2026-2028-targets-at-capital-markets-day/): Philips sets out plan to drive profitable growth to deliver sustainable value, including new, integrated 2030 Impact Ambitions.
- [OPEN Health Announces Strategic Leadership Appointments to Strengthen Enterprise Growth and Decision Quality](https://newswire.pharmashots.com/open-health-announces-strategic-leadership-appointments-to-strengthen-enterprise-growth-and-decision-quality/): New York and London, Feb.
- [Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan](https://newswire.pharmashots.com/curium-group-peptidream-and-pdradiopharma-enroll-first-patient-to-registrational-clinical-trial-of-lu-psma-it-for-prostate-cancer-in-japan/): A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
- [Curium Announces a Strategic Investment of Over €32 million in Saclay, France](https://newswire.pharmashots.com/curium-announces-a-strategic-investment-of-over-e32-million-in-saclay-france/): PARIS, June 01, 2026 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, today announced at the Choose France summit in Versailles, a major industrial investment program in France to the value of €32 million.
- [Disney and Philips bring together beloved storytelling and innovative technology to support kids undergoing MRI exams](https://newswire.pharmashots.com/disney-and-philips-bring-together-beloved-storytelling-and-innovative-technology-to-support-kids-undergoing-mri-exams/): Amsterdam, the Netherlands and Burbank, Calif.
- [Callio Therapeutics to Present Phase 1 Trial Design of CLIO-8221, Novel Dual-Payload ADC, at ASCO 2026](https://newswire.pharmashots.com/callio-therapeutics-to-present-phase-1-trial-design-of-clio-8221-novel-dual-payload-adc-at-asco-2026/): SEATTLE and SINGAPORE, May 27, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics, a biotherapeutics company advancing dual-payload antibody-drug conjugates (ADCs) with a targeted, multi-mechanism approach to cancer treatment, today announced that it will present a trial-in-progress poster highlighting the Phase 1 trial design of CLIO-8221 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-June 2) in Chicago.
- [Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC](https://newswire.pharmashots.com/junshi-biosciences-announces-primary-endpoints-met-in-final-analysis-of-phase-3-study-for-perioperative-toripalimab-plus-chemotherapy-for-resectable-stage-ii-iii-nsclc/): SHANGHAI, May 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (“NEOTORCH”, NCT04158440) of the company’s product toripalimab in combination with platinum-containing doublet chemotherapy as perioperative treatment for resectable stage II-III non-small cell lung cancer (“NSCLC”) patients has finished its final analysis.
- [Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation](https://newswire.pharmashots.com/cosmos-health-releases-2026-2029-guidance-targeting-200m-revenue-71m-gross-profit-and-44m-adjusted-ebitda-by-2029-building-an-innovative-high-margin-healthcare-platform-with-s/): May 26, 2026 09:34 ET | Source: Cosmos Health Inc.
- [AGC Biologics to Manufacture Teikoku Seiyaku's rhMMP-7 Drug Substance](https://newswire.pharmashots.com/agc-biologics-to-manufacture-teikoku-seiyakus-rhmmp-7-drug-substance/): AGC Biologics to provide process development and GMP manufacturing for a novel therapy, leveraging its global microbial network across Germany and Japan.
- [The hidden impact of veterinary care: new insights from a global survey of veterinarians](https://newswire.pharmashots.com/the-hidden-impact-of-veterinary-care-new-insights-from-a-global-survey-of-veterinarians/): a new global survey of 1,000+ veterinarians across 51 countries shows there is far more going on than meets the eye.
- [CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU](https://newswire.pharmashots.com/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu/): Ingelheim, Germany - Boehringer Ingelheim’s JASCAYD® (nerandomilast) has been recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF).
- [China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis](https://newswire.pharmashots.com/china-approves-hernexeos-as-first-targeted-oral-treatment-option-for-her2-mutant-advanced-nsclc-at-initial-diagnosis/): Expedited approval as an initial treatment in China follows U.S.
- [Together for Steatotic Liver Disease - The Hidden NCDs: SLD as the Next Global Public Health Priority](https://newswire.pharmashots.com/together-for-steatotic-liver-disease-the-hidden-ncds-sld-as-the-next-global-public-health-priority/): Geneva, Switzerland, May 22, 2026 (GLOBE NEWSWIRE) -- Yesterday, Global Liver Institute (GLI), in collaboration with the Egyptian Ministry of Health and Population, convened a high-level policy event, on the sidelines of the Seventy-Ninth World Health Assembly (WHA79) to translate this global policy milestone into coordinated action.
- [Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026](https://newswire.pharmashots.com/boehringer-ingelheims-oncology-portfolio-shows-strong-promise-across-multiple-cancers-at-asco-2026/): Ingelheim, Germany and Ridgefield, Conn., US –At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Boehringer Ingelheim will present new data from across its robust oncology clinical development program.
- [The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults](https://newswire.pharmashots.com/the-european-medicines-agency-accepts-tevas-marketing-authorization-application-for-olanzapine-long-acting-injectable-tev-749-for-the-treatment-of-schizophrenia-in-adults/): The olanzapine long-acting injectable (TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.
- [Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma](https://newswire.pharmashots.com/junshi-biosciences-announces-approval-of-toripalimab-nda-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma/): SHANGHAI, May 21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the new drug application (NDA) for toripalimab in combination with disitamab vedotin for patients with HER2-expressing (which is defined as achieving a score of 1+, 2+ or 3+ in HER2 immunohistochemistry test), locally advanced or metastatic urothelial carcinoma (UC) was approved by the National Medical Products Administration (NMPA).
- [Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia](https://newswire.pharmashots.com/hanmi-pharmaceutical-partners-with-organon-to-export-combination-therapies-to-southeast-asia/): Shin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, Organon Asia Pacific Cluster, met at Organon’s Malaysia office to discuss the expansion of Hanmi’s combination therapies into the Southeast Asian market.
- [Curia Completes Upgrade of API Aseptic Suites in Valladolid, Spain](https://newswire.pharmashots.com/curia-completes-upgrade-of-api-aseptic-suites-in-valladolid-spain/): May 19, 2026 09:00 ET | Source: Curia Global, Inc.
- [Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease](https://newswire.pharmashots.com/risen-pharma-announces-initiation-of-phase-2-clinical-trial-of-rp902-for-mild-cognitive-impairment-due-to-alzheimers-disease/): SHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) -- Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced the initiation of a Phase 2 clinical study in China of RP902, an oral small-molecule drug developed to address significant unmet medical needs in patients with Alzheimer's disease.
- [Philips highlights advances in imaging and physiology to support complex PCI at EuroPCR 2026](https://newswire.pharmashots.com/philips-highlights-advances-in-imaging-and-physiology-to-support-complex-pci-at-europcr-2026/): Amsterdam, the Netherlands – As cardiac procedures become more complex, interventional cardiologists must balance the need for precise imaging and decision-making with growing pressure to reduce radiation exposure for both patients and staff.
- [Philips introduces SmartIQ to address the trade-off between image quality and radiation dose in coronary procedures](https://newswire.pharmashots.com/philips-introduces-smartiq-to-address-the-trade-off-between-image-quality-and-radiation-dose-in-coronary-procedures/): Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Philips SmartIQ, a breakthrough coronary imaging technology for its Azurion image-guided therapy.
- [Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution](https://newswire.pharmashots.com/fitch-upgrades-teva-to-investment-grade-amid-pivot-to-growth-execution/): TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact](https://newswire.pharmashots.com/teva-study-finds-only-23-of-younger-adults-with-mood-disorders-and-tardive-dyskinesia-td-symptoms-are-formally-diagnosed-with-td-despite-widespread-impact/): PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- [Philips to deliver vital technology for hospital-at-home care for up to 15,000 patients annually in Region Stockholm](https://newswire.pharmashots.com/philips-to-deliver-vital-technology-for-hospital-at-home-care-for-up-to-15000-patients-annually-in-region-stockholm/): Stockholm, Sweden - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that a consortium composed of Philips, Cuviva and Vingmed has been selected to support Region Stockholm’s hospital-at-home initiative, enabling hospital-level care to be delivered in patients’ homes across the region.
- [JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment](https://newswire.pharmashots.com/jascayd-nerandomilast-approved-in-japan-advancing-global-access-to-a-new-ipf-and-ppf-treatment/): Boehringer Ingelheim today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved JASCAYD® (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF).
- [Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock](https://newswire.pharmashots.com/zymeworks-announces-share-repurchase-program-of-up-to-125-million-of-its-common-stock/): May 14, 2026 16:05 ET | Source: Zymeworks Inc.
- [Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations](https://newswire.pharmashots.com/chengdu-origen-and-vanotech-announce-khn921-investigational-new-drug-application-clearance-by-the-us-fda-for-the-treatment-of-hypertrophic-cardiomyopathy-hcm-associated-with-mybpc3-mutations/): Investigational New Drug application for KHN921 received “study may proceed” from the US FDA.
- [TekniPlex Healthcare to Present Recyclable Blister Packaging Solutions at The Pharma Days 2026](https://newswire.pharmashots.com/tekniplex-healthcare-to-present-recyclable-blister-packaging-solutions-at-the-pharma-days-2026/): The presentation will examine PPWR minimization-driven blister innovations, including recyclable and recycled pharmaceutical grades.
- [Noted Vaccine Researchers Uğur Şahin and Özlem Türeci Awarded Sabin Vaccine Institute’s Albert B. Sabin Gold Medal; Genomic Scientist Senjuti Saha of Bangladesh Receives Rising Star Award](https://newswire.pharmashots.com/noted-vaccine-researchers-ugur-sahin-and-ozlem-tureci-awarded-sabin-vaccine-institutes-albert-b-sabin-gold-medal-genomic-scientist-senjuti-saha-of-bangladesh-receives-rising-star-award/): WASHINGTON, May 13, 2026 (GLOBE NEWSWIRE) -- The 2026 Sabin Awards were presented yesterday at the National Academy of Sciences building in Washington, D.C., with Professor Uğur Şahin, MD, and Professor Özlem Türeci, MD, receiving the Sabin Vaccine Institute’s Albert B.
- [Zymeworks Announces Participation in Upcoming Investor Conferences](https://newswire.pharmashots.com/zymeworks-announces-participation-in-upcoming-investor-conferences/): May 13, 2026 06:00 ET | Source: Zymeworks Inc.
- [Adagene to Participate in Two Upcoming Investor Conferences](https://newswire.pharmashots.com/adagene-to-participate-in-two-upcoming-investor-conferences/): May 12, 2026 08:30 ET | Source: Adagene Inc.
- [Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases](https://newswire.pharmashots.com/boehringer-ingelheim-licenses-preclinical-antibody-program-from-immunitas-therapeutics-to-advance-treatments-for-chronic-inflammatory-diseases/): The first‑in‑class antibody program is designed to selectively target pathogenic cells, with the potential to deliver deeper and more durable disease control than current therapies.
- [Enlitic’s Ensight Goes Live at RHCNZ, Advancing Radiology Workflow Efficiency in New Zealand](https://newswire.pharmashots.com/enlitics-ensight-goes-live-at-rhcnz-advancing-radiology-workflow-efficiency-in-new-zealand/): LOVELAND, Colo., May 11, 2026 (GLOBE NEWSWIRE) -- Enlitic, a global leader in radiology and imaging data, today announced the successful go-live of its Ensight platform at RHCNZ Medical Imaging Group (RHCNZ), New Zealand’s largest private radiology provider.
- [First Participant Dosed in AskBio Phase 1/Phase 2 Gene Therapy Trial of AB-1009 for Late-Onset Pompe Disease (LOPD)](https://newswire.pharmashots.com/first-participant-dosed-in-askbio-phase-1-phase-2-gene-therapy-trial-of-ab-1009-for-late-onset-pompe-disease-lopd/): May 11, 2026 08:00 ET | Source: AskBio Inc.
- [Dark Horse Consulting Group and KunTuo Announce Memorandum of Understanding Providing Cell and Gene Therapy Developers with an Accelerated Path to Clinical Development in China](https://newswire.pharmashots.com/dark-horse-consulting-group-and-kuntuo-announce-memorandum-of-understanding-providing-cell-and-gene-therapy-developers-with-an-accelerated-path-to-clinical-development-in-china/): WALNUT CREEK, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and KunTuo Medical Research and Development (Beijing) Co., Ltd.
- [BASF Agricultural Solutions successfully commissions new fermentation plant for crop protection products in Ludwigshafen](https://newswire.pharmashots.com/basf-agricultural-solutions-successfully-commissions-new-fermentation-plant-for-crop-protection-products-in-ludwigshafen/): Ludwigshafen, Germany, May 11, 2026 – BASF Agricultural Solutions has successfully commissioned its BioHub, a new fermentation plant for biological and biotechnology-based crop protection products, at the Ludwigshafen site.
- [Philips shareholders approve all proposals at the AGM 2026](https://newswire.pharmashots.com/philips-shareholders-approve-all-proposals-at-the-agm-2026/): Appointment of John DeFord (American, 1962) as new member of the Supervisory Board, with effect from May 8, 2026.
- [Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease](https://newswire.pharmashots.com/angelini-pharma-to-acquire-catalyst-pharmaceuticals-for-4-1-billion-usd-3-5-billion-euros-entering-the-u-s-market-and-consolidating-its-leadership-in-brain-health-and-rare-disease/): The transaction marks Angelini Pharma's entry into the U.S.
- [CARBOGEN AMCIS Shanghai Site achieves successful outcome in Unannounced NMPA GMP Inspection](https://newswire.pharmashots.com/carbogen-amcis-shanghai-site-achieves-successful-outcome-in-unannounced-nmpa-gmp-inspection/): BUBENDORF, Switzerland, May 06, 2026 (GLOBE NEWSWIRE) -- CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, today announces its Shanghai facility has successfully completed an unannounced Good Manufacturing Practice (GMP) inspection by China’s National Medical Products Administration (NMPA), with no observations.
- [Philips delivers strong order intake, comparable sales growth and margin expansion in Q1; 2026 outlook reiterated](https://newswire.pharmashots.com/philips-delivers-strong-order-intake-comparable-sales-growth-and-margin-expansion-in-q1-2026-outlook-reiterated/): “We delivered a good start to 2026, with strong order intake growth at 6%, comparable sales growth of 4% and margin expansion of 40 basis points, reflecting disciplined execution against our plan in an uncertain macro-environment.
- [Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026](https://newswire.pharmashots.com/smithnephew-drives-progress-in-chronic-wound-care-with-allevyncomplete-care-dressing-and-renasys-edge-tnpwt-set-to-launch-at-ewma-2026/): Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound Management Association (EWMA) Conference, Bremen between 6-8 May 2026.
- [SK pharmteco Achieves SBTi Validation for 2040 Net-Zero Science-Based Targets](https://newswire.pharmashots.com/sk-pharmteco-achieves-sbti-validation-for-2040-net-zero-science-based-targets/): May 05, 2026 09:03 ET | Source: SK pharmteco Inc.
- [Ingredion Incorporated Reports First Quarter 2026 Results](https://newswire.pharmashots.com/ingredion-incorporated-reports-first-quarter-2026-results/): WESTCHESTER, Ill., May 05, 2026 (GLOBE NEWSWIRE) -- Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to the food and beverage manufacturing industry, today reported its first quarter 2026 results.
- [Teva to Present at the BofA Securities Health Care Conference](https://newswire.pharmashots.com/teva-to-present-at-the-bofa-securities-health-care-conference/): PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial](https://newswire.pharmashots.com/dr-falk-pharma-and-renexxion-announce-positive-results-on-naronapride-in-gastroparesis-from-the-global-phase-2b-move-it-trial/): May 04, 2026 08:00 ET | Source: Dr.
- [EnGeneIC Announces First Patient Dosed in Recurrent Glioblastoma Clinical Trial](https://newswire.pharmashots.com/engeneic-announces-first-patient-dosed-in-recurrent-glioblastoma-clinical-trial/): SYDNEY, May 01, 2026 (GLOBE NEWSWIRE) -- EnGeneIC Limited today announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGeneIC Dream Vector) therapy in patients with recurrent glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer.
- [Former Stryker Medical Division President Brad Saar Joins Sonablate Board to Support Growth of Non-Invasive Prostate Cancer Treatment](https://newswire.pharmashots.com/former-stryker-medical-division-president-brad-saar-joins-sonablate-board-to-support-growth-of-non-invasive-prostate-cancer-treatment/): CHARLOTTE, N.C., April 30, 2026 (GLOBE NEWSWIRE) -- Sonablate, a medical technology company focused on non-invasive prostate cancer treatment using high-intensity focused ultrasound (HIFU), today announced the appointment of Brad Saar, former president of Stryker’s Medical Division, to its Board of Directors.
- [Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy](https://newswire.pharmashots.com/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-tevas-pivot-to-growth-strategy/): Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations.
- [Boehringer Ingelheim and Eko Health Inc. launch new AI-based solution that detects heart murmurs in dogs](https://newswire.pharmashots.com/boehringer-ingelheim-and-eko-health-inc-launch-new-ai-based-solution-that-detects-heart-murmurs-in-dogs/): INGELHEIM, Germany, and SAN FRANCISCO, US - Boehringer Ingelheim, a global leader in animal health, and Eko Health, a leader in AI-powered cardiac and pulmonary disease detection, announced the launch of an innovative solution to detect, visualize, and grade heart murmurs in dogs.
- [Enlitic Announces Full Integration with Sectra, Expanding Access for Sectra Customers](https://newswire.pharmashots.com/enlitic-announces-full-integration-with-sectra-expanding-access-for-sectra-customers/): LOVELAND, Colo., April 29, 2026 (GLOBE NEWSWIRE) -- Enlitic today announced the completion of its integration with Sectra, enabling Enlitic to support Sectra customers directly with its Ensight platform.
- [Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial](https://newswire.pharmashots.com/boehringer-ingelheims-novel-glucagon-glp-1-dual-agonist-survodutide-achieved-significant-weight-loss-of-16-6-delivering-meaningful-metabolic-improvement-in-people-with-obesity-or-overweight-i/): Ingelheim, Germany.
- [AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance](https://newswire.pharmashots.com/agc-biologics-wins-2026-fierce-outsourcing-award-for-leadership-in-regulatory-and-quality-compliance/): April 27, 2026 11:59 ET | Source: AGC Biologics, Inc.
- [Dark Horse Consulting Group and Porton Advanced Announce Memorandum of Understanding Providing a Streamlined Path to Conducting IITs in China](https://newswire.pharmashots.com/dark-horse-consulting-group-and-porton-advanced-announce-memorandum-of-understanding-providing-a-streamlined-path-to-conducting-iits-in-china/): WALNUT CREEK, Calif.
- [Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML](https://newswire.pharmashots.com/kyowa-kirin-and-kura-oncology-initiate-japanese-phase-2-registration-directed-trial-of-ziftomenib-in-r-r-npm1-m-aml/): TOKYO and SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc.
- [Philips launches new Bridge Plus Occlusion Balloon to help manage rare but life-threatening SVC tears during lead extraction](https://newswire.pharmashots.com/philips-launches-new-bridge-plus-occlusion-balloon-to-help-manage-rare-but-life-threatening-svc-tears-during-lead-extraction/): Bridge Plus was built upon proven Bridge Occlusion Balloon technology, used in more than 50,000 U.S.
- [Philips receives FDA 510(k) clearance for its Rembra platform, expanding access to faster, more precise CT imaging across frontline care and cancer treatment planning](https://newswire.pharmashots.com/philips-receives-fda-510k-clearance-for-its-rembra-platform-expanding-access-to-faster-more-precise-ct-imaging-across-frontline-care-and-cancer-treatment-planning/): Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received 510(k) clearance from the U.S.
- [Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026](https://newswire.pharmashots.com/zymeworks-presents-new-phase-1-data-for-zw191-a-folate-receptor-alpha-targeting-adc-at-aacr-annual-meeting-2026/): April 21, 2026 17:30 ET | Source: Zymeworks Inc.
- [New data for Smith+Nephew’s CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant demonstrates superior pain relief and functional gains at 5-years](https://newswire.pharmashots.com/new-data-for-smithnephews-cartiheal%e2%97%8a-agili-c%e2%97%8a-cartilage-repair-implant-demonstrates-superior-pain-relief-and-functional-gains-at-5-years/): Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces further compelling evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its CARTIHEAL AGILI-C Cartilage Repair Implant recently published in the American Journal of Sports Medicine (AJSM).
- [Dark Horse Consulting Group’s Acquisition of CJ PARTNERS Provides Regional Expansion](https://newswire.pharmashots.com/dark-horse-consulting-groups-acquisition-of-cj-partners-provides-regional-expansion/): WALNUT CREEK, Calif.
- [Essential Pharma 旗下公司 Renaissance Pharma Limited 用于治疗高危神经母细胞瘤的 Daretabart (hu1418K322A) 获得 FDA 快速通道认定，并通过 IND 审评](https://newswire.pharmashots.com/essential-pharma-%e6%97%97%e4%b8%8b%e5%85%ac%e5%8f%b8-renaissance-pharma-limited-%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e9%ab%98%e5%8d%b1%e7%a5%9e%e7%bb%8f%e6%af%8d%e7%bb%86%e8%83%9e%e7%98%a4%e7%9a%84-d/): 英国 – 2026 年 4 月 21 日 – Essential Pharma 旗下专注于研发阶段资产的公司 Renaissance Pharma Limited 今天宣布，美国食品和药品管理局 (FDA) 已授予其新型抗 GD2 单克隆抗体 Daretabart (hu1418K322A) 快速通道认定资质，这种正在开发的药物用于治疗罕见儿童癌症 — 高危神经母细胞瘤 (HRNB)。
- [Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026](https://newswire.pharmashots.com/junshi-biosciences-presents-results-from-js207-pd-1-vegf-bsab-phase-2-combo-studies-and-js212-egfr-her3-adc-fih-phase-1-2-study-at-aacr-2026/): SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that early clinical results from four studies across its innovative pipeline were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, featuring: the recombinant humanized anti-EGFR/HER3 bispecific antibody-drug conjugate (ADC) JS212, the anti-PD-1/VEGF bispecific antibody JS207, and the anti-CTLA-4 monoclonal antibody JS007.
- [Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK’s Knowledge Quarter](https://newswire.pharmashots.com/boehringer-ingelheim-expands-investment-in-computational-innovation-with-new-ai-accelerator-in-uks-knowledge-quarter/): Ingelheim, Germany, and London, UK – Boehringer Ingelheim today announced the expansion of its global Computational Innovation footprint with the launch of a new center for AI and machine learning in King’s Cross, London, UK, part of the Knowledge Quarter ecosystem.
- [Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types](https://newswire.pharmashots.com/adagene-presents-two-posters-at-aacr-2026-with-new-data-highlighting-muzastotugs-potential-as-a-backbone-combination-therapy-for-multiple-tumor-types/): April 17, 2026 16:01 ET | Source: Adagene Inc.
- [Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform](https://newswire.pharmashots.com/zymeworks-presents-new-preclinical-data-at-aacr-2026-highlighting-broad-antibody-drug-conjugate-programs-including-novel-ras-targeting-platform/): April 17, 2026 15:00 ET | Source: Zymeworks Inc.
- [Philips receives FDA 510(k) clearance for Verida, the world’s first AI-powered detector-based spectral CT*, advancing diagnostic precision across clinical applications](https://newswire.pharmashots.com/philips-receives-fda-510k-clearance-for-verida-the-worlds-first-ai-powered-detector-based-spectral-ct-advancing-diagnostic-precision-across-clinical-applications/): Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received U.S.
- [Wellcome Leap Announces $2 Million Prize in $50 Million Quantum for Bio Challenge Program](https://newswire.pharmashots.com/wellcome-leap-announces-2-million-prize-in-50-million-quantum-for-bio-challenge-program/): April 16, 2026 08:00 ET | Source: Wellcome Leap Inc.
- [Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine](https://newswire.pharmashots.com/beamion-lung-1-study-results-for-zongertinib-in-treatment-naive-patients-with-her2-mutant-advanced-nsclc-published-in-the-new-england-journal-of-medicine/): This press release is not intended for US or UK media.
- [Svetlana Mojsov, one of the Scientists behind Ozempic, and Mathematician Carlos Kenig, who Decoded Laws of Motion, Honored as King Faisal Prize 2026 Laureates](https://newswire.pharmashots.com/svetlana-mojsov-one-of-the-scientists-behind-ozempic-and-mathematician-carlos-kenig-who-decoded-laws-of-motion-honored-as-king-faisal-prize-2026-laureates/): Riyadh, Saudi Arabia, April 15, 2026 (GLOBE NEWSWIRE) -- On the evening of April 15, HRH Prince Turki Alfaisal, Acting Chairman of the Board of Trustees of King Faisal Foundation, and King Faisal Prize Secretary General Dr.
- [Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners](https://newswire.pharmashots.com/teva-launches-home-ground-schizophrenia-community-a-new-online-resource-hub-for-people-living-with-schizophrenia-and-their-care-partners/): PARSIPPANY, N.J. and TEL AVIV, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- [Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas](https://newswire.pharmashots.com/boehringer-ingelheim-and-zai-lab-announce-collaboration-on-dll3-targeting-t-cell-engager-and-adc-combination-in-small-cell-lung-cancer-and-other-neuroendocrine-carcinomas/): Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
- [Callio Therapeutics to Present Poster on CLIO-8221, a Novel Dual-Payload Antibody-Drug Conjugate, at AACR 2026](https://newswire.pharmashots.com/callio-therapeutics-to-present-poster-on-clio-8221-a-novel-dual-payload-antibody-drug-conjugate-at-aacr-2026/): SEATTLE and SINGAPORE, April 15, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics, a biotherapeutics company advancing dual-payload antibody-drug conjugates (ADCs) with a targeted, multi-mechanism approach to cancer treatment, today announced a poster presentation on CLIO-8221 at the American Association of Cancer Research (AACR) Annual Meeting 2026 (April 17-22, San Diego).
- [Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics](https://newswire.pharmashots.com/community-routes-access-to-mental-health-care-provides-continued-funding-for-mental-health-services-at-free-charitable-clinics/): SANTA BARBARA, Calif.
- [Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board](https://newswire.pharmashots.com/adagene-adds-industry-veteran-peter-lebowitz-to-scientific-and-strategic-advisory-board/): April 14, 2026 07:00 ET | Source: Adagene Inc.
- [Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer](https://newswire.pharmashots.com/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit-in-pivotal-phase-3-rasolute-302-clinical-trial-in-patients-with-metastatic-pancreatic-cancer/): April 13, 2026 08:00 ET | Source: Revolution Medicines, Inc.
- [ProSomnus® Receives FDA Class II Clearance for RPMO2 OSA Device](https://newswire.pharmashots.com/prosomnus-receives-fda-class-ii-clearance-for-rpmo2-osa-device/): April 13, 2026 06:00 ET | Source: ProSomnus Sleep Technologies, Inc.
- [Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows](https://newswire.pharmashots.com/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows/): LENZELTA® is a new vaccine significantly reducing the incidence and severity of clinical mastitis in vaccinated cows and heifers1.
- [Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer](https://newswire.pharmashots.com/boehringer-ingelheim-to-evaluate-innovative-combination-of-dll3-targeting-t-cell-engager-plus-pd-l1-vegf-a-bispecific-antibody-in-small-cell-lung-cancer/): Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore complementary immuno-oncology mechanisms in extensive‑stage small cell lung cancer.
- [Smith+Nephew’s REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*](https://newswire.pharmashots.com/smithnephews-regeneten%e2%97%8a-bioinductive-implant-shows-post-operative-recovery-times-halved-and-high-healing-rates-for-partial-thickness-rotator-cuff-tears1/): “We conducted a randomised controlled study of patients with symptomatic partial-thickness rotator cuff tears and found that those patients treated with the tendon sparing REGENETEN Bioinductive Implant recovered functional independence much faster than patients treated with standard surgery,” said Dr.
- [Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth](https://newswire.pharmashots.com/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth/): April 09, 2026 06:00 ET | Source: Zymeworks Inc.
- [Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program](https://newswire.pharmashots.com/ecuador-free-of-rabies-project-accelerates-progress-toward-eliminating-dog-mediated-rabies-supported-by-boehringer-ingelheims-stop-rabies-program/): • Ecuador aims to become one of the first rabies free countries in Latin America.
- [iHerb Named Exclusive International Retailer for Kylie Jenner’s k2o](https://newswire.pharmashots.com/iherb-named-exclusive-international-retailer-for-kylie-jenners-k2o/): April 08, 2026 09:01 ET | Source: iHerb Holdings, Inc.
- [AliveCor Expands AI-Powered 12-lead Cardiac Diagnostics to Vietnam, Advancing Access to Early Detection and Modernized Cardiac Care](https://newswire.pharmashots.com/alivecor-expands-ai-powered-12-lead-cardiac-diagnostics-to-vietnam-advancing-access-to-early-detection-and-modernized-cardiac-care/): April 07, 2026 18:54 ET | Source: AliveCor Inc.
- [HeartFocus and Inteleos Launch First AI Cardiac POCUS Certification](https://newswire.pharmashots.com/heartfocus-and-inteleos-launch-first-ai-cardiac-pocus-certification/): April 07, 2026 11:24 ET | Source: Inteleos, Inc.
- [Saladax Biomedical to Expand International Access to Drug Level Testing for Psychiatry and Oncology](https://newswire.pharmashots.com/saladax-biomedical-to-expand-international-access-to-drug-level-testing-for-psychiatry-and-oncology/): April 07, 2026 09:00 ET | Source: Saladax Biomedical, Inc.
- [Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials](https://newswire.pharmashots.com/fortrea-unveils-fortrea-intelligent-technology-to-help-sponsors-and-sites-run-smarter-more-integrated-trials/): DURHAM, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global clinical research organization (CRO), today unveiled Fortrea Intelligent Technology™(FIT), a suite of innovative technology solutions designed to transform clinical trial operations.
- [Egg Medical Launches EggNest™ Complete Flex: Apron-Free Protection Without Construction, Downtime or Disruption](https://newswire.pharmashots.com/egg-medical-launches-eggnest-complete-flex-apron-free-protection-without-construction-downtime-or-disruption/): April 06, 2026 09:00 ET | Source: Egg Medical, Inc.
- [Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs](https://newswire.pharmashots.com/adagene-announces-pricing-of-us70-0-million-public-offering-of-adss/): April 02, 2026 07:10 ET | Source: Adagene Inc.
- [Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)](https://newswire.pharmashots.com/adagene-announces-clinical-collaboration-with-incyte-to-evaluate-muzastotug-adg126-in-combination-with-incytes-tgfsr2xpd-1-bispecific-antibody-inca33890-in-patients-with-microsatellite-st/): April 02, 2026 07:01 ET | Source: Adagene Inc.
- [Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response](https://newswire.pharmashots.com/updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-late-line-patients-with-microsatellite-stable-colorectal-cancer-demonstrate-improved-durability-o/): April 02, 2026 07:00 ET | Source: Adagene Inc.
- [Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update](https://newswire.pharmashots.com/adagene-reports-full-year-2025-financial-results-and-provides-corporate-update/): April 01, 2026 17:00 ET | Source: Adagene Inc.
- [Zymeworks Appoints Kristin Stafford as Chief Financial Officer](https://newswire.pharmashots.com/zymeworks-appoints-kristin-stafford-as-chief-financial-officer/): April 01, 2026 06:00 ET | Source: Zymeworks Inc.
- [AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure](https://newswire.pharmashots.com/askbio-announces-completion-of-enrollment-in-phase-2-clinical-trial-of-ab-1002-investigational-gene-therapy-for-heart-failure/): April 01, 2026 02:40 ET | Source: AskBio Inc.
- [Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein](https://newswire.pharmashots.com/standing-ovation-raises-34-2-million-to-scale-up-its-breakthrough-technology-for-producing-dairy-proteins-through-precision-fermentation-offering-a-sovereign-and-sustainable-response-to-the-surge-in/): Paris, 31 March 2026 - Standing Ovation, a French precision fermentation pioneer producing next-generation proteins, has announced a $34.2 million (€30 million) Series B financing round, including $28.5 million in equity (€25 million), led jointly by the Ecotechnologies 2 fund—managed on behalf of the French government by Bpifrance as part of the France 2030 initiative— and Crédit Mutuel Innovation, alongside its existing investors—Astanor, Bel Group, Seventure Partners, GoodStartUp, and Big Idea Ventures—joined by Danone Ventures, Angelor, Newtree, and Noshaq.
- [Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)](https://newswire.pharmashots.com/teva-gains-biosimilar-momentum-with-u-s-fda-approval-of-ponlimsi-denosumab-adet-and-dual-filing-acceptance-for-biosimilar-candidate-to-xolair-omalizumab/): Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.
- [Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate](https://newswire.pharmashots.com/zymeworks-receives-u-s-fda-fast-track-designation-for-zw191-an-fr%ce%b1-targeting-antibody-drug-conjugate/): March 30, 2026 06:00 ET | Source: Zymeworks Inc.
- [Nucleus Brings Genetic Optimization to India and the Middle East Through Leading IVF Networks](https://newswire.pharmashots.com/nucleus-brings-genetic-optimization-to-india-and-the-middle-east-through-leading-ivf-networks/): Indira IVF and Abu Ghosh Fertility Group join the Nucleus IVF+ Network, as families seek a more complete picture of their future child’s health.
- [FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair](https://newswire.pharmashots.com/fda-clears-philips-ai-solution-that-provides-real-time-guidance-during-complex-minimally-invasive-heart-valve-repair/): Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received U.S.
- [Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.](https://newswire.pharmashots.com/io-therapeutics-inc-announces-publication-in-scientific-reports-nature-of-studies-showing-synergistic-efficacy-of-its-rxr-agonist-irx4204-with-the-standard-of-care-drug-lenalidomide-again/): March 25, 2026 12:15 ET | Source: Io Therapeutics, Inc.
- [Philips launches IntraSight Plus to simplify coronary interventions and advance precision care](https://newswire.pharmashots.com/philips-launches-intrasight-plus-to-simplify-coronary-interventions-and-advance-precision-care/): Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the launch of its intuitive interventional guidance platform, IntraSight Plus, which is cleared for clinical use in the USA and Europe.
- [Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025](https://newswire.pharmashots.com/boehringer-ingelheim-delivers-on-late-stage-pipeline-with-two-key-launches-grows-sales-by-7-3-in-a-successful-2025/): Ingelheim, March 25, 2026 – Boehringer Ingelheim successfully delivered on key launches in its Human Pharma business in 2025, bringing two medicines with FDA Breakthrough Therapy designation for lung cancer and pulmonary fibrosis to market in the second half of 2025.
- [SK pharmteco and Prozomix Announce Strategic Collaboration to Enhance Biocatalysis Capabilities for Global Drug Manufacturing](https://newswire.pharmashots.com/sk-pharmteco-and-prozomix-announce-strategic-collaboration-to-enhance-biocatalysis-capabilities-for-global-drug-manufacturing/): March 24, 2026 09:03 ET | Source: SK pharmteco Inc.
- [Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant](https://newswire.pharmashots.com/philips-remains-no-1-in-medtech-at-european-patent-office-and-the-largest-dutch-patent-applicant/): Philips ranks No.
- [Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid](https://newswire.pharmashots.com/press-release-sanofi-and-regenerons-dupixent-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid/): Paris and Tarrytown, NY, March 24, 2026.
- [Philips and Imricor launch cardiac interventional MR lab solution, expanding longstanding collaboration](https://newswire.pharmashots.com/philips-and-imricor-launch-cardiac-interventional-mr-lab-solution-expanding-longstanding-collaboration/): The solution combines Philips' high-performance 1.5T MRI platform and advanced interventional workflow capabilities with Imricor's exclusive portfolio of systems and consumables for MR-guided cardiac interventions.
- [TekniPlex Healthcare Brings Materials Science- Led Medical Device Solutions to Southeast Asia at Medical Fair 2026](https://newswire.pharmashots.com/tekniplex-healthcare-brings-materials-science-led-medical-device-solutions-to-southeast-asia-at-medical-fair-2026/): At Booth 2C01, the company will highlight how customized medical-grade compounds, precision tubing, value-added processing, and healthcare solutions help regional OEMs develop and scale high-performance healthcare products.
- [Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates](https://newswire.pharmashots.com/junshi-biosciences-announces-2026-interim-financial-results-and-provides-corporate-updates/): SHANGHAI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2026 interim financial results and provided corporate updates.
- [Philips selected for ARPA-H program to advance AI-enabled robotic stroke care](https://newswire.pharmashots.com/philips-selected-for-arpa-h-program-to-advance-ai-enabled-robotic-stroke-care/): Cambridge, MA, USA and Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received an up to US$33.7 million award under the Advanced Research Projects Agency for Health (ARPA-H, an agency within the U.S.
- [U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma](https://newswire.pharmashots.com/u-s-fda-approves-ziihera-zanidatamab-hrii-with-and-without-tislelizumab-plus-chemotherapy-in-first-line-her2-advanced-gastroesophageal-adenocarcinoma/): August 25, 2026 10:23 ET | Source: Zymeworks Inc.
- [Philips prices EU green bond for EUR 650M](https://newswire.pharmashots.com/philips-prices-eu-green-bond-for-eur-650m/): Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 650 million fixed rate notes due 2034 (the “Notes”) under its European Medium Term Note (EMTN) program.
- [Spieren voor Spieren wins Dutch F1® Allwyn Global Community Award to transform lives through adaptive sport](https://newswire.pharmashots.com/spieren-voor-spieren-wins-dutch-f1-allwyn-global-community-award-to-transform-lives-through-adaptive-sport/): The F1® Allwyn Global Community Award 2026 trophy presented to Monique Maks (Director) and Ronald de Boer (former footballer and ambassador) of winning local charity Spieren voor Spieren at the FORMULA 1® HEINEKEN DUTCH GRAND PRIX 2026 in the Netherlands.
- [Adagene to Participate in Three Upcoming Investor Conferences](https://newswire.pharmashots.com/adagene-to-participate-in-three-upcoming-investor-conferences/): August 20, 2026 08:00 ET | Source: Adagene Inc.
- [U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome](https://newswire.pharmashots.com/u-s-fda-accepts-tevas-new-drug-application-nda-and-grants-priority-review-for-ecopipam-a-first-in-class-investigational-therapy-for-pediatric-patients-with-tourette-syndrome/): PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- [Amlan International to Sponsor Technical Symposium at 2026 Arkansas Nutrition Conference](https://newswire.pharmashots.com/amlan-international-to-sponsor-technical-symposium-at-2026-arkansas-nutrition-conference/): CHICAGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Amlan International, the animal health business of Oil-Dri Corporation of America, will serve as the Technical Symposium Sponsor at the 2026 Arkansas Nutrition Conference in Little Rock, Arkansas.
- [Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics](https://newswire.pharmashots.com/smithnephew-and-imperial-college-london-launch-centre-to-accelerate-innovation-in-surgical-robotics/): Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, and Imperial College London have launched a five-year partnership to deliver breakthrough research and innovation for robotic surgery for musculoskeletal conditions.
- [One Dog's Legacy Becomes GAMGEE](https://newswire.pharmashots.com/one-dogs-legacy-becomes-gamgee/): A Media Snippet accompanying this announcement is available by clicking on this link.
- [Smith+Nephew’s new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options](https://newswire.pharmashots.com/smithnephews-new-flow-flextend-coblation-wand-improves-access%c2%b9-and-resection-efficiency%c2%b2-for-complex-hip-procedures-vs-fixed-angle-options/): Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a breakthrough in RF resection technology for hip with its new FLOW FLEXTEND COBLATION Wand.
- [Optimi Health Establishes Discretionary Equity Facility](https://newswire.pharmashots.com/optimi-health-establishes-discretionary-equity-facility/): August 14, 2026 16:55 ET | Source: Optimi Health Corp.
- [Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates](https://newswire.pharmashots.com/adagene-reports-six-months-2026-financial-results-and-provides-corporate-updates/): August 12, 2026 07:30 ET | Source: Adagene Inc.
- [Rampart Withdraws Appeal of USPTO’s Invalidation Decision](https://newswire.pharmashots.com/rampart-withdraws-appeal-of-usptos-invalidation-decision/): August 11, 2026 15:47 ET | Source: Egg Medical, Inc.
- [Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy](https://newswire.pharmashots.com/moodys-ratings-upgrades-teva-to-investment-grade-reflecting-the-ongoing-execution-of-pivot-to-growth-strategy/): TEL AVIV, Israel, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [Dark Horse Consulting Group Expands into China, Appoints Kang Liu as Senior Director, Head of China](https://newswire.pharmashots.com/dark-horse-consulting-group-expands-into-china-appoints-kang-liu-as-senior-director-head-of-china/): WALNUT CREEK, Calif. and SHANGHAI, Aug.
- [Zymeworks Announces Participation in Upcoming Investor Conferences](https://newswire.pharmashots.com/zymeworks-announces-participation-in-upcoming-investor-conferences-2/): August 11, 2026 06:00 ET | Source: Zymeworks Inc.
- [Boehringer Ingelheim expands equine health pipeline with acquisition of Evax AG](https://newswire.pharmashots.com/boehringer-ingelheim-expands-equine-health-pipeline-with-acquisition-of-evax-ag/): Boehringer Ingelheim announced today that it has acquired Evax AG, a Swiss biotech company focused on equine health.
- [Exor and Philips Extend Long-term Relationship Agreement](https://newswire.pharmashots.com/exor-and-philips-extend-long-term-relationship-agreement/): Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Exor N.V.
- [DR H Launches Mind Ease Mask to Advance Personalized Sleep Support Through Smart Wearable Innovation](https://newswire.pharmashots.com/dr-h-launches-mind-ease-mask-to-advance-personalized-sleep-support-through-smart-wearable-innovation/): The intelligent sleep wearable combines 3D light-blocking technology, adjustable temperature control, and immersive audio to create a personalized sleep environment.
- [NORTH Performance Launches Globally with Pre-Sales Site and Founding Athlete Co-Owner Roster](https://newswire.pharmashots.com/north-performance-launches-globally-with-pre-sales-site-and-founding-athlete-co-owner-roster/): DOVER, Del., Aug.
- [Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology](https://newswire.pharmashots.com/curium-acquires-abscint-sa-expanding-pet-radiodiagnostic-pipeline-in-oncology/): BOSTON and LIEGE, Belgium, Aug.
- [Philips expands open patient monitoring ecosystem to help health systems keep sight of patients beyond the bedside](https://newswire.pharmashots.com/philips-expands-open-patient-monitoring-ecosystem-to-help-health-systems-keep-sight-of-patients-beyond-the-bedside/): Amsterdam, Netherlands.
- [RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models](https://newswire.pharmashots.com/rxr-nuclear-receptor-agonists-promote-clearance-of-alpha-synuclein-in-cellular-models/): August 05, 2026 12:30 ET | Source: Io Therapeutics, Inc.
- [Cirrus Therapeutics Strengthens Its Position as a Next-Generation Global Ocular Immunology Leader with Singapore Eye Research Institute (SERI) Collaboration and Additional Financing](https://newswire.pharmashots.com/cirrus-therapeutics-strengthens-its-position-as-a-next-generation-global-ocular-immunology-leader-with-singapore-eye-research-institute-seri-collaboration-and-additional-financing/): August 04, 2026 08:00 ET | Source: Cirrus Therapeutics, Inc.
- [Medela Marks World Breastfeeding Week with Research Contribution and Educational Campaign](https://newswire.pharmashots.com/medela-marks-world-breastfeeding-week-with-research-contribution-and-educational-campaign/): Baar, Switzerland, Aug.
- [Curium Announces Definitive Agreement to Merge with Lantheus](https://newswire.pharmashots.com/curium-announces-definitive-agreement-to-merge-with-lantheus/): August 03, 2026 07:31 ET | Source: Lantheus Holdings, Inc.
- [Smith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation](https://newswire.pharmashots.com/smithnephews-tessa-spatial-surgery-system-granted-de-novo-classification-by-the-fda-sparking-a-generational-leap-in-sports-medicine-for-personalized-planning-and-procedural-innovati/): Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been granted De Novo classification by the U.S.
- [Scientists Turn COVID-19 Immune Memory into a Powerful New Ally Against Cancer](https://newswire.pharmashots.com/scientists-turn-covid-19-immune-memory-into-a-powerful-new-ally-against-cancer/): July 28, 2026 17:37 ET | Source: Celloram Inc.
- [Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome](https://newswire.pharmashots.com/alamar-biosciences-launches-nulisaseq-immune-340-panel-for-comprehensive-profiling-of-the-immune-proteome/): July 28, 2026 16:12 ET | Source: Alamar Biosciences, Inc.
- [AGC Biologics Lands Commercial Manufacturing Agreement for Yokohama Site Worth Hundreds of Millions of Dollars](https://newswire.pharmashots.com/agc-biologics-lands-commercial-manufacturing-agreement-for-yokohama-site-worth-hundreds-of-millions-of-dollars/): July 28, 2026 08:59 ET | Source: AGC Biologics, Inc.
- [Philips delivers solid comparable sales growth and margin in Q2; reiterates full year comparable sales growth outlook; Adjusted EBITA and free cash flow outlook increased to reflect US tariff refund](https://newswire.pharmashots.com/philips-delivers-solid-comparable-sales-growth-and-margin-in-q2-reiterates-full-year-comparable-sales-growth-outlook-adjusted-ebita-and-free-cash-flow-outlook-increased-to-reflect-us-tariff-refund/): “We delivered another solid quarter with comparable sales growth of 4%, driven by all business segments, and strong disciplined execution within an uncertain macro environment.
- [Egg Medical Declares New Era in Fluoroscopy Lab Safety Following Joint Consensus Statement](https://newswire.pharmashots.com/egg-medical-declares-new-era-in-fluoroscopy-lab-safety-following-joint-consensus-statement/): July 22, 2026 15:26 ET | Source: Egg Medical, Inc.
- [Acentra Health Appoints Sreedevi Hegde as Senior Vice President – India Country Head](https://newswire.pharmashots.com/acentra-health-appoints-sreedevi-hegde-as-senior-vice-president-india-country-head/): MCLEAN, Va., July 22, 2026 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions company dedicated to accelerating better health outcomes for government and commercial clients and the populations they serve, today announced the appointment of Sreedevi Hegde as Senior Vice President – India Country Head.
- [Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC](https://newswire.pharmashots.com/junshi-biosciences-announces-acceptance-of-the-supplemental-application-for-toripalimab-plus-chemotherapy-as-perioperative-treatment-for-resectable-stage-%e2%85%b1-%e2%85%b2-nsclc/): SHANGHAI, July 21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental application for toripalimab in combination with platinum-containing chemotherapy as perioperative treatment and subsequent monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage II-III non-small cell lung cancer (NSCLC) has been accepted by the National Medical Products Administration (NMPA).
- [Axiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchange](https://newswire.pharmashots.com/axiom-biosciences-announces-intention-to-become-the-first-u-s-biotech-to-list-on-the-hong-kong-stock-exchange/): SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences, a clinical-stage biotechnology company whose lead regenerative therapy produced positive early results in newborns with severe brain injury, today announced its intention to pursue an initial public offering on the Main Board of The Stock Exchange of Hong Kong (HKEX).
- [A Father's Gift, A World First: Six-Year-Old Becomes First Patient to Receive a Liver Transplant Through a Single Robotic Incision](https://newswire.pharmashots.com/a-fathers-gift-a-world-first-six-year-old-becomes-first-patient-to-receive-a-liver-transplant-through-a-single-robotic-incision/): RIYADH, Saudi Arabia, July 20, 2026 (GLOBE NEWSWIRE) -- A father's decision to give part of his liver to save his son has resulted in a global medical first.
- [European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU](https://newswire.pharmashots.com/european-commission-approves-jascayd-bringing-well-tolerated-novel-oral-treatment-for-ipf-and-ppf-to-the-eu/): Ingelheim, Germany - Boehringer Ingelheim today announced that the European Commission (EC) has granted marketing authorization for JASCAYD® (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF).
- [Society for Medical Decision Making Honors UMIT TIROL and Harvard Professor Uwe Siebert with 2026 Career Achievement Award](https://newswire.pharmashots.com/society-for-medical-decision-making-honors-umit-tirol-and-harvard-professor-uwe-siebert-with-2026-career-achievement-award/): OSLO, Norway, July 16, 2026 (GLOBE NEWSWIRE) -- The Society for Medical Decision Making (SMDM) presented its highest career honor, the 2026 Career Achievement Award, to Professor Uwe Siebert, MPH, MSc, ScD, of UMIT TIROL and Harvard University, recognizing his decades of transformative contributions to medical decision making through groundbreaking research, international leadership, education, and service.
- [Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals](https://newswire.pharmashots.com/angelini-pharma-completes-acquisition-of-catalyst-pharmaceuticals/): The Italian pharma company grows its presence in the U.S.
- [Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development](https://newswire.pharmashots.com/boehringer-ingelheim-strengthens-obesity-pipeline-as-potential-first-in-class-triple-receptor-agonist-bi-3034701-enters-phase-ii-development/): The novel candidate may offer a highly differentiated, complementary therapeutic option within Boehringer Ingelheim's expanding obesity and cardiometabolic portfolio.
- [Persephoni Backs SelSym Biotech to Bring Blood-Type-Agnostic Bleeding Control to the Point of Injury](https://newswire.pharmashots.com/persephoni-backs-selsym-biotech-to-bring-blood-type-agnostic-bleeding-control-to-the-point-of-injury/): RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- Persephoni BioSciences ("Persephoni"), a global venture creation platform, today announced that SelSym Biotech ("SelSym"), a preclinical-stage company developing transformative biomimetic therapies to address critically unmet needs in hemorrhage and wound care, has joined Persephoni's portfolio and will operate out of its Clinical Impact Studio in Research Triangle Park.
- [Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.](https://newswire.pharmashots.com/boehringer-ingelheim-reports-first-half-2026-sales-growth-driven-by-jardiance-and-new-product-launches-in-the-u-s/): Net sales reach EUR 15.8 billion, led by JARDIANCE® and successful U.S.
- [Hummingbird Bioscience Wins APAC Trailblazer Award at 2026 Nebius AI Discovery Awards](https://newswire.pharmashots.com/hummingbird-bioscience-wins-apac-trailblazer-award-at-2026-nebius-ai-discovery-awards/): SINGAPORE, July 14, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscience (“Hummingbird”), a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, today announced that it has won the Asia Pacific Trailblazer Award at the 2026 AI Discovery Awards hosted by Nebius.
- [Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases](https://newswire.pharmashots.com/alamar-biosciences-partners-with-leading-research-universities-to-launch-national-initiative-advancing-blood-based-biomarkers-for-neurodegenerative-diseases/): July 13, 2026 02:30 ET | Source: Alamar Biosciences, Inc.
- [Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling](https://newswire.pharmashots.com/alamar-biosciences-nulisa-data-featured-in-more-than-140-scientific-presentations-at-aaic-2026-highlighting-advances-in-blood-based-alzheimers-biomarker-profiling/): July 10, 2026 06:11 ET | Source: Alamar Biosciences, Inc.
- [Avance Clinical to Showcase Asia and China Growth Strategy at BIO Asia–Taiwan 2026](https://newswire.pharmashots.com/avance-clinical-to-showcase-asia-and-china-growth-strategy-at-bio-asia-taiwan-2026/): ADELAIDE, Australia, July 10, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced its participation in BIO Asia–Taiwan 2026, taking place 15–19 July at the Taipei Nangang Exhibition Center (TaiNEX), Taipei.
- [Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis](https://newswire.pharmashots.com/teva-and-polpharma-biologics-announce-global-licensing-agreement-for-a-biosimilar-candidate-to-ocrevus-ocrelizumab-for-multiple-sclerosis/): Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.
- [European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process](https://newswire.pharmashots.com/european-medicines-agency-expedites-assessment-of-revolution-medicines-daraxonrasib-under-phased-review-process/): July 07, 2026 09:23 ET | Source: Revolution Medicines, Inc.
- [Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research](https://newswire.pharmashots.com/alamar-biosciences-launches-the-first-multiplexed-blood-based-immunoassay-for-emtbr-tau-one-of-the-most-important-biomarkers-in-alzheimers-disease-research/): July 07, 2026 09:12 ET | Source: Alamar Biosciences, Inc.
- [World First: KFSH Jeddah's Single-Session Stem Cell Protocol Sets a New Global Standard Balancing Donor Safety and Treatment Efficiency](https://newswire.pharmashots.com/world-first-kfsh-jeddahs-single-session-stem-cell-protocol-sets-a-new-global-standard-balancing-donor-safety-and-treatment-efficiency/): JEDDAH, Kingdom of Saudi Arabia, July 07, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre in Jeddah has successfully developed and implemented the world’s first protocol of its kind, using an algorithm to accurately estimate the expected stem cell yield from each donor.
- [Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management](https://newswire.pharmashots.com/vivani-medical-enters-into-agreement-with-novo-nordisk-to-evaluate-npm-139-a-miniature-ultra-long-acting-semaglutide-implant-for-chronic-weight-management/): July 07, 2026 07:35 ET | Source: Vivani Medical, Inc.
- [Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results](https://newswire.pharmashots.com/teva-to-advance-its-anti-il-15-antibody-designed-for-quarterly-dosing-into-phase-2b-development-in-vitiligo-following-encouraging-phase-1b-results/): Tuesday, July 7, 2026, at 8:00 a.m. ET to discuss these data.
- [Aztiq Promotes David Olafsson, Danny Major and Eunsun Choi to Partner](https://newswire.pharmashots.com/aztiq-promotes-david-olafsson-danny-major-and-eunsun-choi-to-partner/): July 06, 2026 10:00 ET | Source: Aztiq Consulting ehf.
- [Starlight Children’s Foundation wins British F1® Allwyn Global Community Award to make hospital stays kinder for children](https://newswire.pharmashots.com/starlight-childrens-foundation-wins-british-f1-allwyn-global-community-award-to-make-hospital-stays-kinder-for-children/): The F1® Allwyn Global Community Award 2026 trophy presented to Jonny Wright and Laura Walsh from winning local charity Starlight Children’s Foundation at the FORMULA 1® PIRELLI BRITISH GRAND PRIX 2026 at Silverstone, UK.
- [Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)](https://newswire.pharmashots.com/junshi-biosciences-enters-licensing-collaboration-with-fosun-wanbang-on-roconkibart-il-17a/): SHANGHAI, July 01, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the company has recently entered into a license agreement with Fosun Wanbang Pharma Group (“Fosun Wanbang,” a wholly-owned subsidiary of Fosun Pharma (HKEX: 02196; SSE: 600196).
- [AGC Biologics Expands to Fill-Finish in U.S. Through Strategic Partnership with Pyramid Pharma Services](https://newswire.pharmashots.com/agc-biologics-expands-to-fill-finish-in-u-s-through-strategic-partnership-with-pyramid-pharma-services/): New collaboration delivers streamlined integration from drug substance to drug product, including sterile fill-finish and device assembly for clinical programs.
- [New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome](https://newswire.pharmashots.com/new-analyses-advance-understanding-of-long-term-survival-outcomes-with-mogamulizumab-in-mycosis-fungoides-and-sezary-syndrome/): PRINCETON, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Researchers at the World Congress of Cutaneous Lymphoma 2026 presented two indirect treatment comparison (ITC) analyses examining the impact of mogamulizumab on long-term outcomes, including overall survival (OS), in patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL).
- [Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression](https://newswire.pharmashots.com/optimi-health-completes-psilocybin-export-to-australia-for-patients-with-treatment-resistant-depression/): June 29, 2026 09:00 ET | Source: Optimi Health Corp.
- [New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome](https://newswire.pharmashots.com/new-prosper-data-demonstrate-real-world-impact-of-mogamulizumab-on-symptoms-and-health-related-quality-of-life-in-mycosis-fungoides-and-sezary-syndrome/): PRINCETON, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co.
- [Zymeworks to Acquire Theravance Biopharma, Inc.](https://newswire.pharmashots.com/zymeworks-to-acquire-theravance-biopharma-inc/): June 29, 2026 06:00 ET | Source: Zymeworks Inc.
- [Evaluate Recognized for Artificial Intelligence Innovation in 9th Annual AI Breakthrough Awards Program](https://newswire.pharmashots.com/evaluate-recognized-for-artificial-intelligence-innovation-in-9th-annual-ai-breakthrough-awards-program/): LONDON, June 25, 2026 (GLOBE NEWSWIRE) -- Evaluate, a Norstella company and the leading global provider of market insights for the pharmaceutical industry, today announced that Ask Ella has been named “Enterprise AI Search Solution of the Year” in the 9th annual AI Breakthrough Awards program.
- [SK pharmteco Announces SKyvec™, A Unified, High-Yield Viral Vector Platform Designed to Accelerate Gene Therapy Development from Batch to Bedside](https://newswire.pharmashots.com/sk-pharmteco-announces-skyvec-a-unified-high-yield-viral-vector-platform-designed-to-accelerate-gene-therapy-development-from-batch-to-bedside/): June 23, 2026 09:03 ET | Source: SK pharmteco Inc.
- [Evaluate Releases Annual World Preview Report Revealing Updated Market Forecasts for the Pharmaceutical Industry](https://newswire.pharmashots.com/evaluate-releases-annual-world-preview-report-revealing-updated-market-forecasts-for-the-pharmaceutical-industry/): LONDON, June 23, 2026 (GLOBE NEWSWIRE) -- Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2026 World Preview Report, providing updated insights for the global pharmaceutical market.
- [Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers](https://newswire.pharmashots.com/boehringer-ingelheim-accelerates-precision-oncology-research-with-initiation-of-three-phase-iii-trials-in-hard-to-treat-cancers/): Ingelheim, Germany and Ridgefield, Conn - Boehringer Ingelheim is advancing biomarker-informed approaches and extending precision care across multiple cancers and stages of disease, reinforcing its ambition to bring unprecedented impact and improve long-term outcomes where unmet need remains high.4,5,6 The company has initiated two Phase III clinical trials within the DAREON® program: DAREON®-Lung-1 in small cell lung cancer (SCLC) and DAREON®-NEC-1 in extrapulmonary neuroendocrine carcinoma (epNEC).
- [Avance Clinical Announces Asia Pacific and Mainland China Expansion Ahead of BIO International Convention 2026](https://newswire.pharmashots.com/avance-clinical-announces-asia-pacific-and-mainland-china-expansion-ahead-of-bio-international-convention-2026/): ADELAIDE, Australia, June 19, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced a significant expansion of its Asia Pacific and China operations, reinforcing its position as the leading CRO partner for international biotech companies seeking access to the region’s diverse patient populations, scientific infrastructure, and accelerated clinical trial timelines.
- [Teva Releases Q2 2026 Aide Memoire](https://newswire.pharmashots.com/teva-releases-q2-2026-aide-memoire/): TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome](https://newswire.pharmashots.com/teva-submits-nda-for-ecopipam-a-first-in-class-investigational-therapy-for-pediatric-tourette-syndrome/): NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.
- [Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET](https://newswire.pharmashots.com/teva-to-host-conference-call-to-discuss-second-quarter-2026-financial-results-on-july-29-2026-at-8-a-m-et/): TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [SK pharmteco Announces Strategic Collaboration with Orphan Therapeutics Accelerator for the Development and Manufacturing of Rare Disease Therapies](https://newswire.pharmashots.com/sk-pharmteco-announces-strategic-collaboration-with-orphan-therapeutics-accelerator-for-the-development-and-manufacturing-of-rare-disease-therapies/): June 18, 2026 09:03 ET | Source: SK pharmteco Inc.
- [Court victory paves the way for Curium’s plans to provide targeted radioligand therapy to U.S. patients with GEP-NETs](https://newswire.pharmashots.com/court-victory-paves-the-way-for-curiums-plans-to-provide-targeted-radioligand-therapy-to-u-s-patients-with-gep-nets/): BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- Curium™ is pleased to announce that it has prevailed in the patent dispute brought by Novartis subsidiary Advanced Accelerator Applications against Curium™ concerning Curium’s Lutetium Lu 177 dotatate product.
- [New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF](https://newswire.pharmashots.com/new-analyses-from-fibroneer-trials-suggest-survival-benefit-with-nerandomilast-in-ipf-and-ppf/): Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European Alliance of Associations for Rheumatology (EULAR) 2026 international congresses.
- [Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research](https://newswire.pharmashots.com/optimi-health-launches-standardized-microdose-psilocybin-products-for-clinical-research/): June 16, 2026 08:30 ET | Source: Optimi Health Corp.
- [Healthy Campus in action as d’Annunzio University turns out in force for Chieti Night Run](https://newswire.pharmashots.com/healthy-campus-in-action-as-dannunzio-university-turns-out-in-force-for-chieti-night-run/): A great celebration of sport and community, with d’Annunzio University’s “sea of blue” among the most visible features of the 26th edition of the Chieti Night Run.
- [Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026](https://newswire.pharmashots.com/zymeworks-presents-new-phase-1-data-for-folate-receptor-alpha-targeting-adc-zw191-at-esmo-gynaecological-cancers-congress-2026/): June 14, 2026 18:05 ET | Source: Zymeworks Inc.
- [EAACI Calls for a "Vision Zero" Future Free from Allergy and Asthma Burden](https://newswire.pharmashots.com/eaaci-calls-for-a-vision-zero-future-free-from-allergy-and-asthma-burden/): ZURICH, June 12, 2026 (GLOBE NEWSWIRE) -- As allergic diseases continue to affect hundreds of millions of people worldwide and place growing pressure on healthcare systems, the European Academy of Allergy and Clinical Immunology (EAACI) is calling for a new ambition in global health: Vision Zero, a future free from allergy and asthma burden.
- [Global Fatty Liver Day 2026 builds on WHO Momentum to Drive Urgent Action on Steatotic (fatty) Liver Disease](https://newswire.pharmashots.com/global-fatty-liver-day-2026-builds-on-who-momentum-to-drive-urgent-action-on-steatotic-fatty-liver-disease/): Washington, D.C., June 11, 2026 (GLOBE NEWSWIRE) -- Global Fatty Liver Day 2026 comes at a pivotal moment for liver health worldwide.
- [Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan](https://newswire.pharmashots.com/curium-group-peptidream-and-pdradiopharma-announce-completion-of-patient-dosing-in-clinical-trial-of-64cu-psma-it-for-prostate-cancer-in-japan/): BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc.
- [Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy ](https://newswire.pharmashots.com/teva-closes-acquisition-of-emalex-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-pivot-to-growth-strategy/): Ecopipam, an investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations.
- [Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL](https://newswire.pharmashots.com/kyowa-kirin-to-present-new-complementary-evidence-further-defining-clinical-utility-of-mogamulizumab-in-cutaneous-t-cell-lymphoma-at-2026-wccl/): PRINCETON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co.
- [Fertility Institute of Hawaii Joins Nucleus IVF+ Network as Demand for Genetic Optimization Continues to Expand](https://newswire.pharmashots.com/fertility-institute-of-hawaii-joins-nucleus-ivf-network-as-demand-for-genetic-optimization-continues-to-expand/): June 09, 2026 09:00 ET | Source: Nucleus Genomics Inc.
- [Philips Future Health Index 2026: AI is already saving clinicians time and delivering measurable impact in healthcare](https://newswire.pharmashots.com/philips-future-health-index-2026-ai-is-already-saving-clinicians-time-and-delivering-measurable-impact-in-healthcare/): Amsterdam, the Netherlands – AI is already saving clinicians the equivalent of over 16 working days a year and helping them see more patients, but healthcare systems risk falling behind because of inadequate training and fragmented infrastructure.
- [Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty](https://newswire.pharmashots.com/smithnephew-announces-first-clinical-cases-with-the-next-generation-cori%e2%97%8axt-handheld-robotics-platform-across-knee-and-shoulder-arthroplasty/): Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology.
- [Vantive Highlights Late-Breaking High Clinical Impact Data at ERA Indicating HDx Therapy is a Practical Alternative to Online Hemodiafiltration](https://newswire.pharmashots.com/vantive-highlights-late-breaking-high-clinical-impact-data-at-era-indicating-hdx-therapy-is-a-practical-alternative-to-online-hemodiafiltration/): GLASGOW, Scotland, June 08, 2026 (GLOBE NEWSWIRE) -- Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, reports two late-breaking clinical studies indicating HDx therapy (expanded hemodialysis) enabled by the Theranova dialyzer provides similar (statistically non-inferior) all-cause mortality and major cardiovascular outcomes* compared with online hemodiafiltration (OL-HDF).1,2 The randomized controlled MOTheR trial and interim results from the real-world CONCORDIA study were presented at the 63rd European Renal Association (ERA) Congress, held June 3-6, 2026, in Glasgow, Scotland.
- [Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care](https://newswire.pharmashots.com/tevas-data-on-austedo-deutetrabenazine-tablets-and-austedo-xr-deutetrabenazine-extended-release-tablets-highlight-long-term-advances-in-tardive-dyskinesia-treatment-and-care/): New analysis from the IMPACT-TD Registry demonstrates that treatment with AUSTEDO and AUSTEDO XR led to reductions in Abnormal Involuntary Movement Scale (AIMS) scores in all participants, which were associated with improved activities of daily living.
- [Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity](https://newswire.pharmashots.com/boehringer-ingelheims-survodutide-phase-iii-trial-showed-targeted-34-visceral-and-63-liver-fat-reduction-while-minimizing-lean-mass-loss-in-pre-specified-analysis-supporting-improved-metabo/): The 76-week Phase III SYNCHRONIZE-1 trial investigated survodutide in adults living with obesity or overweight, without type 2 diabetes.
- [EnGeneIC Honored with 2026 Breakthrough in Glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York](https://newswire.pharmashots.com/engeneic-honored-with-2026-breakthrough-in-glioblastoma-biotech-award-at-northwell-foundation-lenox-hill-neurosurgery-brain-cancer-gala-in-new-york/): SYDNEY and NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- EnGeneIC Limited today announced it has been recognized with the Breakthrough in glioblastoma Biotech Award 2026 at the Northwell Foundation, Lenox Hill Neurosurgery Brain Tumor Center Gala event in New York City.
- [Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea](https://newswire.pharmashots.com/teva-presents-new-data-on-austedo-deutetrabenazine-tablets-and-austedo-xr-deutetrabenazine-extended-release-tablets-that-show-patient-and-caregiver-reported-improvements-in-huntington/): These real-world findings reinforce Teva's commitment to advancing innovative treatment options that improve the lives of individuals living with HD chorea and their caregivers.
- [New Health Economic Evidence Shows Health & Cost Benefits When Starting Dialysis at Home](https://newswire.pharmashots.com/new-health-economic-evidence-shows-health-cost-benefits-when-starting-dialysis-at-home/): GLASGOW, Scotland, June 05, 2026 (GLOBE NEWSWIRE) -- Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, today announced results from a newly commissioned health economic study showing that use of home-based peritoneal dialysis (PD), compared with in-center hemodialysis (ICHD) as the initial dialysis modality, is linked to improved patient outcomes and lower overall health system costs.
- [Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®](https://newswire.pharmashots.com/teva-expands-european-biosimilars-portfolio-with-launch-of-ahzantive-aflibercept-biosimilar-to-eylea/): TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [WellSpan Health and Philips Announce Landmark Strategic Alliance, Accelerating Innovation and Research Across Central Pennsylvania and Northern Maryland](https://newswire.pharmashots.com/wellspan-health-and-philips-announce-landmark-strategic-alliance-accelerating-innovation-and-research-across-central-pennsylvania-and-northern-maryland/): Amsterdam and YORK, Pa.
- [Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia](https://newswire.pharmashots.com/iovances-amtagvi-lifileucel-granted-approval-for-the-treatment-of-advanced-melanoma-in-australia/): June 03, 2026 16:05 ET | Source: Iovance Biotherapeutics, Inc.
- [Dark Horse Consulting Group and Altruist Biologics Announce Memorandum of Understanding to Advance Biologics Manufacturing and Development in China](https://newswire.pharmashots.com/dark-horse-consulting-group-and-altruist-biologics-announce-memorandum-of-understanding-to-advance-biologics-manufacturing-and-development-in-china/): WALNUT CREEK, Calif.
- [Inteleos and Medvarsity Partner to Expand Global POCUS Education Access](https://newswire.pharmashots.com/inteleos-and-medvarsity-partner-to-expand-global-pocus-education-access/): New collaboration delivers the POCUS Fundamentals Certificate to clinicians worldwide, creating a structured entry point for point-of-care ultrasound training.
- [Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics](https://newswire.pharmashots.com/alamar-biosciences-makes-home-collected-fingerstick-samples-compatible-with-ultra-high-sensitivity-multiplex-proteomics/): June 02, 2026 14:43 ET | Source: Alamar Biosciences, Inc.
- [Philips receives FDA 510(k) clearance for Elevate Plus for EPIQ Elite and Affiniti, delivering AI advancements in general imaging ultrasound](https://newswire.pharmashots.com/philips-receives-fda-510k-clearance-for-elevate-plus-for-epiq-elite-and-affiniti-delivering-ai-advancements-in-general-imaging-ultrasound/): Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced regulatory clearance in the USA of Elevate Plus, bringing advanced imaging and a suite of AI and automation capabilities to Philips EPIQ Elite and Affiniti, its flagship ultrasound systems.
- [Teva to Present at the Goldman Sachs Global Healthcare Conference](https://newswire.pharmashots.com/teva-to-present-at-the-goldman-sachs-global-healthcare-conference/): PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio](https://newswire.pharmashots.com/resmed-completes-acquisition-of-noctrix-health-expanding-clinical-sleep-health-portfolio/): Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS).
- [Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis](https://newswire.pharmashots.com/teva-to-discontinue-phase-2-topas-msa-study-of-emrusolmin-tev-286-following-interim-futility-analysis/): PARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- [Atos appoints Judith Stewart as Head of Healthcare & Life Sciences, Asia Pacific](https://newswire.pharmashots.com/atos-appoints-judith-stewart-as-head-of-healthcare-life-sciences-asia-pacific/): Perth, Australia – November 2, 2026 - Atos, a global leader of AI-powered digital transformation, today announces the appointment of Judith Stewart as Head of Healthcare & Life Sciences for Asia Pacific, reinforcing the company’s commitment to accelerating growth and innovation across the sector and helping organizations harness the potential of artificial intelligence, sovereign technologies and cybersecurity.
- [Philips launches HyperVue Integrated System in the U.S., bringing advanced coronary imaging and physiology into the cathlab](https://newswire.pharmashots.com/philips-launches-hypervue-integrated-system-in-the-u-s-bringing-advanced-coronary-imaging-and-physiology-into-the-cathlab/): Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced U.S.
- [Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD](https://newswire.pharmashots.com/boehringer-ingelheim-registers-phase-iii-trial-investigating-verducatib-in-copd-2/): Ingelheim, Germany and Ridgefield, Conn., U.S.
- [Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD](https://newswire.pharmashots.com/boehringer-ingelheim-registers-phase-iii-trial-investigating-verducatib-in-copd/): Ingelheim, Germany and Ridgefield, Conn., U.S.
- [Asia-Pacific is rapidly gaining importance as a major pillar in global life science innovation](https://newswire.pharmashots.com/asia-pacific-is-rapidly-gaining-importance-as-a-major-pillar-in-global-life-science-innovation/): Seoul, Korea – Boehringer Ingelheim today highlighted Asia-Pacific’s increasing importance in global life science innovation.
- [Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma](https://newswire.pharmashots.com/junshi-biosciences-announces-the-completion-of-first-patient-dosing-in-the-phase-3-clinical-trial-of-js207-in-combination-with-js007-for-the-first-line-treatment-of-advanced-hepatocellular-carcinoma/): SHANGHAI, Oct. 29, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the first patient dosing has been completed in a multi-center, randomized, controlled, and open-label phase 3 clinical study evaluating the efficacy and safety of the company’s product, recombinant humanized anti-PD-1/VEGF bispecific antibody (code: JS207), in combination with recombinant humanized anti-CTLA-4 monoclonal antibody (code: JS007) compared to toripalimab in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma (JS207-017-III-HCC Study, NCT07823348).
- [Philips launches UniGuide 3D Live Guidance, bringing CT planning into live procedures and extending the capabilities of its Azurion image-guided therapy platform](https://newswire.pharmashots.com/philips-launches-uniguide-3d-live-guidance-bringing-ct-planning-into-live-procedures-and-extending-the-capabilities-of-its-azurion-image-guided-therapy-platform/): New CE-marked solution leverages the industry-leading Philips Azurion platform to integrate CT-derived insights and treatment planning directly into the procedural workflow, helping physicians make informed decisions during treatment.
- [Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subcutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma](https://newswire.pharmashots.com/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subcutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma/): SHANGHAI, China, Oct.
- [Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer](https://newswire.pharmashots.com/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer/): October 28, 2026 07:00 ET | Source: Adagene Inc.
- [Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026](https://newswire.pharmashots.com/junshi-biosciences-announces-final-analysis-results-of-the-phase-3-neotorch-study-at-esmo-congress-2026/): Perioperative toripalimab plus chemotherapy demonstrated significant and durable improvements in event-free survival and overall survival in patients with resectable stage II-III non-small cell lung cancer.
- [Cloudera Launches Cloudera Blueprints, Bringing NVIDIA Agent Toolkit to Enterprise Data Anywhere](https://newswire.pharmashots.com/cloudera-launches-cloudera-blueprints-bringing-nvidia-agent-toolkit-to-enterprise-data-anywhere/): October 27, 2026 09:00 ET | Source: Cloudera, Inc.
- [Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline](https://newswire.pharmashots.com/teva-acquires-worldwide-rights-to-bxcl501-further-expanding-innovative-neuroscience-pipeline/): TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd.
- [Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference](https://newswire.pharmashots.com/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference/): October 27, 2026 07:00 ET | Source: Adagene Inc.
- [Lira Clinical Announces New REGEN Line — A First-of-Its-Kind Breakthrough in Regenerative Skincare](https://newswire.pharmashots.com/lira-clinical-announces-new-regen-line-a-first-of-its-kind-breakthrough-in-regenerative-skincare/): LIVERMORE, Calif., Oct.
- [Newsweek Places KFSH in Top 4% of World’s Smart Hospitals for Digital Maturity and AI](https://newswire.pharmashots.com/newsweek-places-kfsh-in-top-4-of-worlds-smart-hospitals-for-digital-maturity-and-ai/): RIYADH, Saudi Arabia, Oct.
- [Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026](https://newswire.pharmashots.com/zymeworks-presents-new-phase-1-data-for-folate-receptor-alpha-targeting-antibody-drug-conjugate-zw191-at-esmo-congress-2026/): October 24, 2026 02:30 ET | Source: Zymeworks Inc.
- [Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma](https://newswire.pharmashots.com/junshi-biosciences-announces-completion-of-first-patient-dosing-in-the-phase-3-clinical-trial-of-js203-in-combination-with-chemotherapy-for-the-treatment-of-diffuse-large-b-cell-lymphoma/): SHANGHAI, China, Oct.
- [Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3](https://newswire.pharmashots.com/zymeworks-enters-into-an-exclusive-global-license-and-collaboration-agreement-with-roche-for-zw209-a-trispecific-t-cell-engager-targeting-dll3/): October 23, 2026 06:00 ET | Source: Zymeworks Inc.
- [Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development](https://newswire.pharmashots.com/fortrea-and-omico-collaboration-to-advance-biomarker-led-oncology-drug-development/): DURHAM, N.C. and SYDNEY, Oct.
- [Boehringer Ingelheim and Microsoft partner to drive patient-centric and AI-backed clinical development](https://newswire.pharmashots.com/boehringer-ingelheim-and-microsoft-partner-to-drive-patient-centric-and-ai-backed-clinical-development/): Cologne, Germany - Boehringer Ingelheim and Microsoft today announced a strategic collaboration that aims to bring safe and effective therapies to patients sooner fueled by AI.
- [Asimov Announces Adoption of Its AI-Driven Cell Line Development Platform by LG Chem](https://newswire.pharmashots.com/asimov-announces-adoption-of-its-ai-driven-cell-line-development-platform-by-lg-chem/): BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a licensing agreement with South Korea-based LG Chem, a leading global chemical company with a diversified business portfolio spanning across petrochemicals, advanced materials, and life sciences.
- [New JAHA-Published EggNest® Study and Texas State Regulatory Variance Validate Shift Toward Apron-Free Workflows in the Interventional Lab](https://newswire.pharmashots.com/new-jaha-published-eggnest-study-and-texas-state-regulatory-variance-validate-shift-toward-apron-free-workflows-in-the-interventional-lab/): October 21, 2026 09:48 ET | Source: Egg Medical, Inc.
- [Circle CVI joins EXIT-CVD research consortium to advance imaging-informed, personalized cardiovascular care across Europe](https://newswire.pharmashots.com/circle-cvi-joins-exit-cvd-research-consortium-to-advance-imaging-informed-personalized-cardiovascular-care-across-europe/): October 20, 2026 10:00 ET | Source: Circle Cardiovascular Imaging Inc.
- [UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease](https://newswire.pharmashots.com/ueg-week-teva-and-sanofis-duvakitug-maintained-long-term-positive-outcomes-in-new-phase-2b-data-for-ulcerative-colitis-and-crohns-disease/): PARSIPPANY, N.J. and PARIS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- [VIVUS Announces Positive Outcome of European Procedure to Extend QSIVA® (Phentermine/Topiramate MR) to Adolescents with Obesity](https://newswire.pharmashots.com/vivus-announces-positive-outcome-of-european-procedure-to-extend-qsiva-phentermine-topiramate-mr-to-adolescents-with-obesity/): October 19, 2026 09:00 ET | Source: VIVUS B.V.
- [Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma](https://newswire.pharmashots.com/zymeworks-appoints-suzanne-monahan-as-senior-vice-president-commercial-and-general-manager-theravance-biopharma/): October 19, 2026 06:00 ET | Source: Zymeworks Inc.
- [Callio Therapeutics Wins Best New ADC Drug Developer at the 13th World ADC Awards, Presents Across Five Sessions at World ADC San Diego](https://newswire.pharmashots.com/callio-therapeutics-wins-best-new-adc-drug-developer-at-the-13th-world-adc-awards-presents-across-five-sessions-at-world-adc-san-diego/): SAN DIEGO, SEATTLE and SINGAPORE, Oct.
- [Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results](https://newswire.pharmashots.com/zymeworks-announces-participation-in-upcoming-investor-conferences-and-date-of-third-quarter-2026-financial-results/): October 15, 2026 06:00 ET | Source: Zymeworks Inc.
- [EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe](https://newswire.pharmashots.com/exit-cvd-research-consortium-launches-clinical-studies-to-transform-cardiovascular-care-across-europe/): Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the five-year EXIT-CVD research project, co-funded by the European Union Innovative Health Initiative (IHI) and the industry partners.
- [Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH](https://newswire.pharmashots.com/three-year-real-world-study-compares-burosumab-treatment-with-oral-phosphate-and-active-vitamin-d-in-adults-with-xlh/): October 14, 2026 09:05 ET | Source: Kyowa Kirin, Inc.
- [Cority Earns Three G2 Leader Badges Across Two Categories in Fall 2026 Grid® Report](https://newswire.pharmashots.com/cority-earns-three-g2-leader-badges-across-two-categories-in-fall-2026-grid-report/): October 14, 2026 08:00 ET | Source: Cority Software Inc.
- [Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference](https://newswire.pharmashots.com/adagene-to-participate-in-h-c-wainwright-4th-annual-immune-cell-engager-virtual-conference/): October 14, 2026 08:00 ET | Source: Adagene Inc.
- [TekniPlex Healthcare to Showcase Capabilities Enabling the Next Generation of Medical Device Solutions at MD&M Midwest 2026](https://newswire.pharmashots.com/tekniplex-healthcare-to-showcase-capabilities-enabling-the-next-generation-of-medical-device-solutions-at-mdm-midwest-2026/): Company to highlight integrated capabilities spanning custom material formulations, precision extrusion, catheter construction and finished-device assembly.
- [From the ocean to animal health: Acadian launches "TASCO," optimized feed technology aimed at improving resilience and productivity.](https://newswire.pharmashots.com/from-the-ocean-to-animal-health-acadian-launches-tasco-optimized-feed-technology-aimed-at-improving-resilience-and-productivity/): October 13, 2026 08:00 ET | Source: Acadian Seaplants Ltd.
- [Teva to Host R&D Day on Wednesday, November 11 in New York City](https://newswire.pharmashots.com/teva-to-host-rd-day-on-wednesday-november-11-in-new-york-city/): TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [Gates Foundation and Wellcome Leap Commit $100 Million to Reduce Global Stillbirth Rates](https://newswire.pharmashots.com/gates-foundation-and-wellcome-leap-commit-100-million-to-reduce-global-stillbirth-rates/): October 12, 2026 06:00 ET | Source: Wellcome Leap Inc.
- [Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia](https://newswire.pharmashots.com/teva-announces-u-s-food-and-drug-administration-fda-approval-of-weltruza-olanzapine-for-extended-release-injectable-suspension-as-the-first-and-only-once-monthly-subcutaneous-injectable/): Teva will hold an investor call and live webcast on Friday, October 9, 2026, 8:00 a.m.
- [TherapiAI Showcases Agentic AI Platform for Biopharma at BioJapan 2026](https://newswire.pharmashots.com/therapiai-showcases-agentic-ai-platform-for-biopharma-at-biojapan-2026/): YOKOHAMA, Japan, Oct.
- [Medela Establishes Drainology™ as a Global Hub to Advance Evidence-Based Chest Drain Management](https://newswire.pharmashots.com/medela-establishes-drainology-as-a-global-hub-to-advance-evidence-based-chest-drain-management/): Baar, Switzerland, Oct.
- [Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal](https://newswire.pharmashots.com/smithnephews-revolutionary-cartiheal-agili-c-cartilage-repair-implant-launches-in-europe-to-be-featured-at-icrs-summit-in-portugal/): Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe.
- [Curia Invests $28 Million in Sterile API Manufacturing](https://newswire.pharmashots.com/curia-invests-28-million-in-sterile-api-manufacturing/): October 05, 2026 09:00 ET | Source: Curia Global, Inc.
- [Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients](https://newswire.pharmashots.com/journal-of-child-neurology-publishes-review-highlighting-dopamines-role-in-tourette-syndrome-and-ecopipams-selective-d1-receptor-mechanism-for-tourette-syndrome-in-pediatric-patients/): Ecopipam is an investigational, selective D1 (dopamine) receptor antagonist targeting dopaminergic signaling in the brain’s direct motor pathway implicated in Tourette syndrome.
- [Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome](https://newswire.pharmashots.com/teva-presents-new-efficacy-and-safety-data-with-ecopipam-an-investigational-treatment-for-pediatric-patients-with-tourette-syndrome/): PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- [Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes](https://newswire.pharmashots.com/boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-diabetes/): Beyond weight loss, key secondary endpoint results showed that adults treated with survodutide experienced improvements in important cardiometabolic health markers.
- [TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness](https://newswire.pharmashots.com/tapi-technology-api-services-names-serge-rogasik-ceo-to-lead-next-chapter-of-growth-and-competitiveness/): TEL AVIV, Israel, Sept.
- [SK pharmteco Announces $200-Plus Million U.S. Investment to Expand Small Molecule and Peptide Capacity](https://newswire.pharmashots.com/sk-pharmteco-announces-200-plus-million-u-s-investment-to-expand-small-molecule-and-peptide-capacity/): September 30, 2026 09:04 ET | Source: SK pharmteco Inc.
- [Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers](https://newswire.pharmashots.com/hummingbird-bioscience-announces-first-patient-dosed-in-phase-ii-trial-of-hmbd-001-and-cetuximab-in-advanced-squamous-cell-cancers/): SINGAPORE, Sept.
- [TekniPlex Healthcare to Showcase Wearable Drug Delivery, Ophthalmic Innovations, and Pharmaceutical Protection at CPHI Milan 2026](https://newswire.pharmashots.com/tekniplex-healthcare-to-showcase-wearable-drug-delivery-ophthalmic-innovations-and-pharmaceutical-protection-at-cphi-milan-2026/): Wayne, PA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- The materials that protect and deliver medicines are changing.
- [Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million](https://newswire.pharmashots.com/boehringer-ingelheim-investments-into-sustainability-related-programs-and-health-partnerships-to-reach-eur-500-million/): Company investments from the past five years, together with the forecast for 2026, are projected to reach EUR 500 million by year-end 2026, encompassing all expenditure on sustainability-related projects and health partnerships.
- [ProductLife Group completes its transformation into a single, unified group with an end-to-end set of human and digital capabilities across life sciences](https://newswire.pharmashots.com/productlife-group-completes-its-transformation-into-a-single-unified-group-with-an-end-to-end-set-of-human-and-digital-capabilities-across-life-sciences/): PARIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- ProductLife Group (PLG) today completes a multi-year transformation, uniting the 26 businesses it has acquired over six years into a single Group with an end-to-end set of digital and human capabilities across life sciences.
- [Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)](https://newswire.pharmashots.com/teva-continues-biosimilar-momentum-with-u-s-fda-approval-of-degevma-denosumab-adet-a-biosimilar-to-xgeva-denosumab/): DEGEVMA™ is now FDA-approved across all indications of the reference product, Xgeva® (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy.
- [Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer](https://newswire.pharmashots.com/callio-therapeutics-appoints-chris-hassig-phd-as-chief-scientific-officer/): SAN DIEGO and SEATTLE and SINGAPORE, Sept.
- [Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition](https://newswire.pharmashots.com/zymeworks-announces-updated-2026-financial-guidance-and-final-transaction-details-following-theravance-biopharma-acquisition/): September 28, 2026 06:00 ET | Source: Zymeworks Inc.
- [Omotesando Helene Clinic and Maison Privé Clinic Sign Cooperation Agreement on International Medical Exchange and Patient Support](https://newswire.pharmashots.com/omotesando-helene-clinic-and-maison-prive-clinic-sign-cooperation-agreement-on-international-medical-exchange-and-patient-support/): TOKYO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Omotesando Helene Clinic (Japan) and Maison Privé Clinic (South Korea) have signed a Memorandum of Understanding (MOU) to promote medical exchange between the two countries and improve support systems for patients visiting from overseas.
- [Amlan International Sponsors World Dairy Expo Media Room for Fifth Consecutive Year](https://newswire.pharmashots.com/amlan-international-sponsors-world-dairy-expo-media-room-for-fifth-consecutive-year/): CHICAGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Amlan® International, the animal health business of Oil-Dri® Corporation of America, will return to World Dairy Expo as the official Media Room sponsor.
- [Boehringer Ingelheim and WHO Foundation launch global collaboration to close the gap in obesity and metabolic health](https://newswire.pharmashots.com/boehringer-ingelheim-and-who-foundation-launch-global-collaboration-to-close-the-gap-in-obesity-and-metabolic-health/): Ingelheim, Germany - Boehringer Ingelheim and the WHO Foundation today announced a three-year collaboration to accelerate progress on obesity and its related metabolic conditions in resource-limited settings.
- [Flen Health Chooses AGC Biologics to Manufacture Recombinant Enzymes for Next-Generation Wound Treatment](https://newswire.pharmashots.com/flen-health-chooses-agc-biologics-to-manufacture-recombinant-enzymes-for-next-generation-wound-treatment/): September 24, 2026 02:55 ET | Source: AGC Biologics, Inc.
- [Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET](https://newswire.pharmashots.com/teva-to-host-conference-call-to-discuss-third-quarter-2026-financial-results-on-november-3-2026-at-8-a-m-et/): TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [Teva Releases Q3 2026 Aide Memoire](https://newswire.pharmashots.com/teva-releases-q3-2026-aide-memoire/): TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [Zymeworks Completes Acquisition of Theravance Biopharma](https://newswire.pharmashots.com/zymeworks-completes-acquisition-of-theravance-biopharma/): September 23, 2026 16:01 ET | Source: Zymeworks Inc.
- [MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management](https://newswire.pharmashots.com/multimedia-update-smithnephew-launches-the-new-evos-pelvic-plating-system-at-the-2026-orthopedic-trauma-association-ota-annual-meeting-expanding-the-evos-plating-platform-for-pelvic-and/): Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the EVOS PELVIC Plating System, the next evolution of the EVOS plating platform designed to address the unique challenges of pelvic and acetabular surgery.
- [Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management](https://newswire.pharmashots.com/smithnephew-launches-the-new-evos-pelvic-plating-system-at-the-2026-orthopedic-trauma-association-ota-annual-meeting-expanding-the-evos-plating-platform-for-pelvic-and-acetabular-fracture/): Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the EVOS PELVIC Plating System, the next evolution of the EVOS plating platform designed to address the unique challenges of pelvic and acetabular surgery.
- [Boehringer Ingelheim and AWARE launch new Stop Rabies project in Zimbabwe to help protect dogs and communities](https://newswire.pharmashots.com/boehringer-ingelheim-and-aware-launch-new-stop-rabies-project-in-zimbabwe-to-help-protect-dogs-and-communities/): Rabies remains one of the world’s deadliest yet preventable zoonotic diseases, highlighting the need for sustained prevention efforts.
- [Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System](https://newswire.pharmashots.com/natural-design-amplified-smithnephew-announces-fda-510k-clearance-and-first-surgical-cases-of-landmark-total-knee-system/): Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it received 510(k) clearance from the U.S.
- [Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager](https://newswire.pharmashots.com/adagene-announces-nmpa-clearance-of-investigational-new-drug-application-for-adg138-a-novel-her2xcd3-double-masked-bispecific-t-cell-engager/): September 22, 2026 08:00 ET | Source: Adagene Inc.
- [Opterion Health Announces Positive Phase 1 Results for OPT101, Supporting Advancement to Phase 2a](https://newswire.pharmashots.com/opterion-health-announces-positive-phase-1-results-for-opt101-supporting-advancement-to-phase-2a/): Positive Phase 1 results strengthen confidence in OPT101, with SPARC achieving its objectives across all major endpoints, including safety, tolerability, pharmacokinetics and functional activity in patients with moderate/severe chronic kidney disease.
- [Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026](https://newswire.pharmashots.com/smithnephew-to-showcase-leading-shoulder-technologies-for-joint-repair-and-reconstruction-at-icses-2026/): Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Congress for Shoulder and Elbow Surgery (ICSES) in Vancouver from September 22-25.
- [New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients](https://newswire.pharmashots.com/new-teva-study-identifies-the-attributes-that-healthcare-providers-prioritize-when-selecting-a-treatment-for-tardive-dyskinesia-in-older-patients/): PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- [Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs](https://newswire.pharmashots.com/teva-highlights-new-real-world-data-showing-uzedy-risperidone-outperforms-other-long-acting-injectables-in-keeping-schizophrenia-patients-on-treatment-while-reducing-emergency-care-and-health/): PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- [Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults](https://newswire.pharmashots.com/teva-announces-new-olanzapine-lai-tev-749-post-hoc-data-highlighting-high-rates-of-stabilization-and-long-term-efficacy-as-once-monthly-subcutaneous-injectable-for-the-treatment-of-schizophrenia-i/): PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- [Boehringer Ingelheim launches PED Essentials, an online learning resource that gives patients a stronger voice](https://newswire.pharmashots.com/boehringer-ingelheim-launches-ped-essentials-an-online-learning-resource-that-gives-patients-a-stronger-voice/): Patient experience data (PED) are direct insights that patients provide on their symptoms, quality of life, treatment preferences and unmet needs.
- [Philips-led projects win ITEA awards for advancing AI-enabled healthcare innovation](https://newswire.pharmashots.com/philips-led-projects-win-itea-awards-for-advancing-ai-enabled-healthcare-innovation/): Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that two Philips-led public-private research collaborations have received ITEA Awards of Excellence 2026 for advancing AI-enabled innovation in healthcare.
- [Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care](https://newswire.pharmashots.com/teva-launches-longactingimpact-com-to-advance-understanding-of-earlier-effective-and-uninterrupted-schizophrenia-care/): PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- [Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease](https://newswire.pharmashots.com/cambium-bio-secures-a10-85-million-to-initiate-pivotal-phase-3-trial-of-elate-ocular-a-potential-first-in-class-biologic-for-dry-eye-disease/): SYDNEY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Cambium Bio Limited (ASX: CMB) (“Cambium Bio” or the “Company”), a clinical-stage regenerative medicine company developing biologic therapies for ophthalmology, today announced that it has secured an A$10.85 million funding package to initiate its pivotal Phase 3 trial of Elate Ocular® in moderate to severe dry eye disease (“DED”).
- [Hummingbird Bioscience Appoints Dr. James Garner as President](https://newswire.pharmashots.com/hummingbird-bioscience-appoints-dr-james-garner-as-president/): SINGAPORE, Sept.
- [Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs](https://newswire.pharmashots.com/curium-announces-fda-approval-of-bexlutry-lutetium-lu-177-dotatate-injection-for-adults-with-sstr-positive-gep-nets/): BOSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Curium™ announced today that the U.S.
- [Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy](https://newswire.pharmashots.com/teva-begins-trading-ordinary-shares-directly-on-the-nyse-marking-a-milestone-in-its-pivot-to-growth-strategy/): PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [Avance Clinical Wins ANZCham's Australia-Taiwan Business Excellence Award in Taiwan](https://newswire.pharmashots.com/avance-clinical-wins-anzchams-australia-taiwan-business-excellence-award-in-taiwan/): TAIPEI, Taiwan, Sept.
- [Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology](https://newswire.pharmashots.com/adagene-announces-that-third-arc-bio-has-selected-first-lead-candidate-under-amended-strategic-collaboration-for-development-of-masked-cd3-t-cell-engagers-utilizing-safebody-technology/): September 10, 2026 08:00 ET | Source: Adagene Inc.
- [Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes](https://newswire.pharmashots.com/teva-announces-successful-pricing-of-4-9-billion-equivalent-senior-notes/): TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [VVMF, Australia's First Viral Vector CDMO Receives TGA Manufacturing Licence](https://newswire.pharmashots.com/vvmf-australias-first-viral-vector-cdmo-receives-tga-manufacturing-licence/): September 10, 2026 01:08 ET | Source: VIRAL VECTOR MANUFACTURING FACILITY PTY. LTD.
- [Dark Horse Consulting Group Marks the Opening of Its Shanghai Office with Ribbon Cutting Ceremony](https://newswire.pharmashots.com/dark-horse-consulting-group-marks-the-opening-of-its-shanghai-office-with-ribbon-cutting-ceremony/): WALNUT CREEK, Calif. and SHANGHAI, Sept.
- [Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer](https://newswire.pharmashots.com/callio-therapeutics-appoints-zachary-hornby-as-chief-executive-officer/): SAN DIEGO and SEATTLE and SINGAPORE, Sept.
- [Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates](https://newswire.pharmashots.com/adagene-achieves-milestone-in-collaboration-with-exelixis-for-advancement-of-safebody-antibody-drug-conjugate-candidates/): September 09, 2026 08:00 ET | Source: Adagene Inc.
- [Accumulus Technologies Announces Acquisition by Eir Partners to Accelerate Next Phase of Growth](https://newswire.pharmashots.com/accumulus-technologies-announces-acquisition-by-eir-partners-to-accelerate-next-phase-of-growth/): SAN FRANCISCO, Sept.
- [From Smart Pet Hardware to AI-Powered Pet Health Management: PetSuper Showcases the Future of Pet Care at IFA 2026](https://newswire.pharmashots.com/from-smart-pet-hardware-to-ai-powered-pet-health-management-petsuper-showcases-the-future-of-pet-care-at-ifa-2026/): BERLIN, Sept. 09, 2026 (GLOBE NEWSWIRE) -- PetSuper, a smart pet technology brand focused on developing intelligent products that enhance everyday pet care, made its debut at IFA 2026.
- [Teva Announces Launch of Offering of Senior Notes](https://newswire.pharmashots.com/teva-announces-launch-of-offering-of-senior-notes/): TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline](https://newswire.pharmashots.com/sp-global-ratings-upgrades-teva-to-bbb-marking-third-credit-rating-upgrade-in-recent-months-and-reflecting-strong-execution-and-financial-discipline/): TEL AVIV, Israel, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [Curia Celebrates Expansion of Albuquerque Facility with Ribbon-Cutting Ceremony](https://newswire.pharmashots.com/curia-celebrates-expansion-of-albuquerque-facility-with-ribbon-cutting-ceremony/): September 03, 2026 12:00 ET | Source: Curia Global, Inc.
- [Philips advances women’s health ultrasound with new single-transducer solution](https://newswire.pharmashots.com/philips-advances-womens-health-ultrasound-with-new-single-transducer-solution/): Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced the eV14-2v transvaginal transducer, expanding its obstetrics and gynecology ultrasound portfolio.
- [Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential](https://newswire.pharmashots.com/teva-announces-positive-topline-results-from-phase-2a-study-in-celiac-disease-for-its-anti-il-15-antibody-further-validating-its-pipeline-in-a-product-potential/): Teva-discovered TEV ‘408, a novel anti-IL-15 monoclonal antibody, demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage vs placebo following a single subcutaneous dose.
- [Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials](https://newswire.pharmashots.com/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials/): Includes a 60,000 sq. ft.
- [Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September](https://newswire.pharmashots.com/teva-to-present-at-morgan-stanley-j-p-morgan-and-bofa-investor-conferences-in-september/): TEL AVIV, Israel, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd.
- [Boehringer Ingelheim launches SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis](https://newswire.pharmashots.com/boehringer-ingelheim-launches-scovella-in-great-britain-the-first-approved-therapy-for-insulin-dysregulation-in-horses-a-main-cause-of-laminitis/): "Laminitis is one of the most common and welfare-impacting conditions we face in equine practice.
- [Health-ISAC® Invests in APAC with Key Staff Addition in Australia](https://newswire.pharmashots.com/health-isac-invests-in-apac-with-key-staff-addition-in-australia/): MELBOURNE, Australia, Sept.
- [Kyowa Kirin Announces Agreement with U.S. Administration to Reduce Treatment Costs for Americans](https://newswire.pharmashots.com/kyowa-kirin-announces-agreement-with-u-s-administration-to-reduce-treatment-costs-for-americans/): August 31, 2026 16:07 ET | Source: Kyowa Kirin, Inc.
- [Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.](https://newswire.pharmashots.com/teva-and-trump-administration-announce-intent-to-reach-agreement-around-affordable-medicines-and-supply-chain-security-for-patients-in-the-u-s/): PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- [XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation](https://newswire.pharmashots.com/xyra-announces-first-patient-dosed-in-europe-in-the-phase-2-3-harbor-af-study-of-budiodarone-in-paroxysmal-and-persistent-atrial-fibrillation/): LOS ALTOS, California, Aug.
- [Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy ](https://newswire.pharmashots.com/teva-announces-proposed-acquisition-of-a-novel-neuroscience-product-reinforcing-disciplined-business-development-approach-under-pivot-to-growth-strategy/): BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

## Pages

- [Home](https://newswire.pharmashots.com/home/): Reach media, investors, and decision-makers with clarity and credibility.

## Optional

- [Agent (MCP protocol)](websites-agents.hostinger.com/newswire.pharmashots.com/mcp)

[comment]: # (Generated by Hostinger Tools Plugin)